Verona Pharma (VRNA) 20-F 19 Mar 19 2018 FY Annual report (foreign) Financial data

DEI

DEI	12 Months Ended
	Dec. 31, 2018shares
Document Information [Abstract]
Document Type	20-F
Entity Filer Category	Accelerated Filer
Document Fiscal Year Focus	2018
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Period Focus	FY
Entity Registrant Name	Verona Pharma PLC
Entity Central Index Key	0001657312
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	No
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Number of shares outstanding (in shares)	105,326,637

CONSOLIDATED STATEMENT OF FINAN

CONSOLIDATED STATEMENT OF FINANCIAL POSITION - GBP (£) £ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Non-current assets:
Goodwill	£ 441	£ 441
Intangible assets	2,134	1,969
Property, plant and equipment	21	16
Total non-current assets	2,596	2,426
Current assets:
Prepayments and other receivables	2,463	1,810
Current tax receivable	4,499	5,006
Short term investments	44,919	48,819
Cash and cash equivalents	19,784	31,443
Total current assets	71,665	87,078
Total assets	74,261	89,504
Capital and reserves attributable to equity holders:
Share capital	5,266	5,251
Share premium	118,862	118,862
Share-based payment reserve	7,923	5,022
Accumulated loss	(69,117)	(49,254)
Total equity	62,934	79,881
Current liabilities:
Derivative financial instrument	2,492	1,273
Trade and other payables	7,733	7,154
Tax payable—U.S. Operations	0	169
Total current liabilities	10,225	8,596
Non-current liabilities:
Assumed contingent obligation	996	875
Deferred income	106	152
Total non-current liabilities	1,102	1,027
Total equity and liabilities	£ 74,261	£ 89,504

CONSOLIDATED STATEMENT OF COMPR

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Profit or loss [abstract]
Research and development costs	£ (19,294)	£ (23,717)	£ (4,522)
General and administrative costs	(6,297)	(6,039)	(2,498)
Operating loss	(25,591)	(29,756)	(7,020)
Finance income	2,783	7,018	1,841
Finance expense	(1,325)	(2,465)	(794)
Loss before taxation	(24,133)	(25,203)	(5,973)
Taxation — credit	4,232	4,706	954
Loss for the year	(19,901)	(20,497)	(5,019)
Other comprehensive income / (loss):
Exchange differences on translating foreign operations	38	(29)	43
Total comprehensive loss attributable to owners of the Company	£ (19,863)	£ (20,526)	£ (4,976)
Loss per ordinary share — basic and diluted (pence per share)	£ (0.189)	£ (0.234)	£ (0.150)

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS £ in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2018GBP (£)	Dec. 31, 2017GBP (£)	Dec. 31, 2016GBP (£)
Cash used in operating activities:
Loss before taxation	£ (24,133)	£ (25,203)	£ (5,973)
Finance income	(2,783)	(7,018)	(1,841)
Finance expense	1,325	2,465	794
Share-based payment charge	2,901	2,919	577
Increase in prepayments and other receivables	(640)	(161)	(1,809)
Increase in trade and other payables	531	5,363	1,068
Depreciation of property, plant and equipment	8	7	10
Loss on disposal of property plant and equipment	0	0	3
Amortization of intangible assets	90	116	52
Cash used in operating activities	(22,701)	(21,512)	(7,119)
Cash inflow from taxation	4,590	816	1,533
Net cash used in operating activities	(18,111)	(20,696)	(5,586)
Cash flow from investing activities:
Interest received	883	128	87
Purchase of plant and equipment	(13)	(9)	(13)
Payment for patents and computer software	(255)	(208)	(115)
Purchase of short term investments	(59,700)	(54,465)	0
Maturity of short term investments	64,366	5,085	0
Net cash generated from / (used in) investing activities	5,281	(49,469)	(41)
Cash flow from financing activities:
Gross proceeds from issue of shares and warrants	0	0	44,750
Gross proceeds from the April 2017 Global Offering	0	70,032
Transaction costs on issue of shares and warrants	0	0	(2,910)
Transaction costs on April 2017 Global Offering	0	(6,786)	(636)
Net cash generated from financing activities	0	63,246	41,204
Net (decrease) / increase in cash and cash equivalents	(12,830)	(6,919)	35,577
Cash and cash equivalents at the beginning of the year	31,443	39,785	3,524
Effect of exchange rates on cash and cash equivalents	1,171	(1,423)	684
Cash and cash equivalents at the end of the year	£ 19,784	£ 31,443	£ 39,785

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY - GBP (£) £ in Thousands	Total	Share Capital	Share Premium	Share-based Payment Reserve	Total Accumulated Losses
Beginning balance at Dec. 31, 2015	£ 5,434	£ 1,010	£ 26,650	£ 1,526	£ (23,752)
Loss for the year	(5,019)				(5,019)
Exchange differences on translating foreign operations	43				43
Total comprehensive loss for the year	(4,976)				(4,976)
New share capital issued	35,707	1,556	34,151
Transaction costs on share capital issued	(2,325)		(2,325)
Share options exercised during the year	52	2	50
Share-based payments	577			577
Ending balance at Dec. 31, 2016	34,469	2,568	58,526	2,103	(28,728)
Loss for the year	(20,497)				(20,497)
Exchange differences on translating foreign operations	(29)				(29)
Total comprehensive loss for the year	(20,526)				(20,526)
New share capital issued	70,325	2,677	67,648
Transaction costs on share capital issued	(7,453)		(7,453)
Share options exercised during the year	147	6	141
Share-based payments	2,919			2,919
Ending balance at Dec. 31, 2017	79,881	5,251	118,862	5,022	(49,254)
Loss for the year	(19,901)				(19,901)
Exchange differences on translating foreign operations	38				38
Total comprehensive loss for the year	(19,863)				(19,863)
New share capital issued	15	15	0
Share-based payments	2,901			2,901
Ending balance at Dec. 31, 2018	£ 62,934	£ 5,266	£ 118,862	£ 7,923	£ (69,117)

General information

General information	12 Months Ended
	Dec. 31, 2018
Disclosure of notes and other explanatory information [Abstract]
General information	General information Verona Pharma plc and its subsidiaries (the "Company") are a clinical-stage biopharmaceutical group focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The Company is a public limited company, which is dual listed on the AIM, a market of the London Stock Exchange, and The Nasdaq Global Market. The company is incorporated and domiciled in the United Kingdom. The address of the registered office is 1 Central Square, Cardiff, CF10 1FS, United Kingdom. The Company has two subsidiaries, Verona Pharma Inc. and Rhinopharma Limited ("Rhinopharma"), both of which are wholly owned. On February 10, 2017, the Company effected a 50 -for-1 consolidation of its shares. All references to ordinary shares, options and warrants, as well as share, per share and related information in these consolidated financial statements have been adjusted to reflect the consolidation as if it had occurred at the beginning of the earliest period presented. On April 26, 2017, the Company announced the closing of its global offering of an aggregate of 47,399,001 new ordinary shares, consisting of the initial public offering in the United States of 5,768,000 American Depositary Shares (“ADSs”) at a price of $ 13.50 per ADS and the private placement in Europe of 1,255,001 ordinary shares at a price of £ 1.32 per ordinary share, for gross proceeds of $80 million (the “Global Offering”). Each ADS offered represents eight ordinary shares of the Company. The ordinary shares offered were allotted and issued in a concurrent private placement in Europe and other countries outside of the United States and Canada. In addition, the Chairman of Verona Pharma’s board of directors, Dr. David Ebsworth, and an existing shareholder agreed to subscribe for 254,099 new ordinary shares at a price of £ 1.32 per ordinary share in a shareholder private placement separate from the Global Offering (the “Shareholder Private Placement”), contingent on and concurrent with the Global Offering and generating additional gross proceeds of £ 0.3 million. On May 15 and May 23, 2017, pursuant to the Global Offering, the underwriters purchased an additional 733,738 ADSs, representing 5,869,904 ordinary shares, at a price of $ 13.50 per ADS, for additional gross proceeds of $ 9.9 million bringing the total gross proceeds in the Global Offering to $ 89.9 million (£ 70.0 million). Including the Shareholder Private Placement, the total gross proceeds of the capital raising amounted to $ 90.3 million (£ 70.3 million). The ADSs trade on The Nasdaq Global Market under the symbol “VRNA” and Verona Pharma’s ordinary shares trade on AIM under the symbol “VRP”.

Accounting policies

Accounting policies	12 Months Ended
	Dec. 31, 2018
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract]
Accounting policies	Accounting policies A summary of the principal accounting policies, all of which have been applied consistently throughout the year, is set out below. Basis of preparation The consolidated financial statements of the Company have been prepared in accordance with International Financial Reporting Standards ("IFRSs") as issued by the International Accounting Standards Board and IFRS Interpretations Committee applicable to companies reporting under IFRS. The consolidated financial statements have been prepared under the historical cost convention, with the exception of derivative financial instruments which have been measured at fair value. The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in note 4. Going concern During the year ended December 31, 2018 , the Company had a loss of £19.9 million ( 2017 : £20.5 million ). As of December 31, 2018 , the Company had net assets of £62.9 million ( 2017 : £79.9 million ) of which £64.7 million ( 2017 : £80.3 million) was cash and cash equivalents and short term investments. The operation of the Company is currently being financed from funds that the Company raised from share placings. In April and May 2017, the Company raised $90.3 million ( £70.3 million ) from the Global Offering and the Shareholder Private Placement. On July 29, 2016, the Company raised gross proceeds of £44.7 million from a placing, subscription and open offer (the "July 2016 Placement"). These funds are being used primarily to support the development of ensifentrine in chronic obstructive pulmonary disease ("COPD") and other chronic respiratory diseases, as well as corporate and general administrative expenditures. The Directors believe that the Company has sufficient funds to complete the current clinical trials, to cover corporate and general administration costs and for it to comply with all commitments for at least 12 months from the end of the reporting date and, accordingly, are satisfied that the going concern basis remains appropriate for the preparation of these consolidated financial statements. Business combination The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement and the fair value of any pre-existing equity interest in the subsidiary. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. Goodwill arising on acquisitions is capitalized and is subject to an impairment review, both annually and when there are indications that the carrying value may not be recoverable. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses. Basis of consolidation These consolidated financial statements include the financial statements of Verona Pharma plc and its wholly owned subsidiaries Verona Pharma, Inc. and Rhinopharma. The acquisition method of accounting was used to account for the acquisition of Rhinopharma. Inter-company transactions, balances and unrealized gains on transactions between group companies are eliminated. Verona Pharma Inc. and Rhinopharma adopt the same accounting policies as the Company. Foreign currency translation Items included in the Company's consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates ("the functional currency"). The consolidated financial statements are presented in pounds sterling ("£"), which is the functional and presentational currency of the Company. Transactions in foreign currencies are recorded using the rate of exchange ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the rate of exchange ruling at the balance sheet date and the gains or losses on translation are included in the Consolidated Statement of Comprehensive Income. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the original transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The assets and liabilities of foreign operations are translated into pounds sterling at the rate of exchange ruling at the balance sheet date. Income and expenses are translated at weighted average exchange rates for the period. The exchange differences arising on translation for consolidation are recognized in Other Comprehensive Income. Cash and cash equivalents Cash and cash equivalents includes cash in hand, deposits held at call with banks and other short-term highly liquid investments with original maturities of three months or less. Deferred taxation Deferred tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realized or the deferred liability is settled. Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will be available against which the temporary differences can be utilized. Research and development costs Capitalization of expenditure on product development commences from the point at which technical feasibility and commercial viability of the product can be demonstrated and the Company is satisfied that it is probable that future economic benefits will result from the product once completed. No such costs have been capitalized to date, given the early stage of the Company's product candidate development. Expenditure on research and development activities that do not meet the above criteria is charged to the Consolidated Statement of Comprehensive Income as incurred. Property, plant and equipment Property, plant and equipment are stated at cost, net of depreciation and any provision for impairment. Cost includes the original purchase price of the asset and the costs attributable to bringing the asset to its working condition for its intended use. Depreciation is calculated so as to write off the cost less their estimated residual values, on a straight-line basis over the expected useful economic lives of the assets concerned. The principal annual periods used for this purpose are: Computer hardware 3 years Office equipment 5 years Intangible assets and goodwill (a) Goodwill Goodwill arises on the acquisition of subsidiaries and represents the excess of the consideration transferred over the fair value of the identifiable net assets acquired. (b) Patents Patent costs associated with the preparation, filing, and obtaining of patents are capitalized and amortized on a straight-line basis over the estimated useful lives of the patents of ten years . (c) Computer software Amortization is calculated so as to write off the cost less estimated residual values, on a straight-line basis over the expected useful economic life of two years. (d) In-process research & development ("IP R&D") IP R&D assets acquired through business combinations which, at the time of acquisition, have not reached technical feasibility are recognized at fair value. The amounts are capitalized and are not amortized but are subject to impairment testing until completion, abandonment of the projects or when the research findings are commercialized through a revenue generating project. The Company determines whether intangible assets (including goodwill) are impaired on an annual basis or where there is an impairment indicator and this requires the estimation of the higher of fair value less costs of disposal and value in use. Upon successful completion or commercialization of the relevant project, IP R&D will be reclassified to developed technology. The Company will make a determination as to the then useful life of the developed technology, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. In case of abandonment the asset will be impaired. Impairment of intangible assets, goodwill and non-financial assets Goodwill and intangible assets that have an indefinite useful life and intangible assets not ready to use are not subject to amortization. These assets are tested annually for impairment or more frequently if impairment indicators exist. Non-financial assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value (less costs of disposal) and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows, which are largely independent of the cash flows from other assets or group of assets (cash generating units "CGUs"). Goodwill is allocated to CGUs for the purpose of impairment testing. The allocation is made to those CGUs or groups of CGUs that are expected to benefit from the business combination in which the goodwill arose. The units or group of units are identified at the lowest level at which goodwill is monitored for internal management purposes, being the operating segments. The Company is a single cash generating unit. Goodwill that arose on the acquisition of Rhinopharma has been thus allocated to this single CGU. IP R&D is tested for impairment at this level as well, since it is the lowest level at which independent cash flows can be identified. Non-financial assets, other than goodwill, that have been previously impaired are reviewed for possible reversal of the impairment at each subsequent reporting date. Employee Benefits (a) Pension The Company operates a defined contribution pension scheme for UK employees. Contributions payable for the year are charged to the Consolidated Statement of Comprehensive Income. The contributions are recognized as employee benefit expense when they are due. Differences between contributions payable in the year and contributions actually paid are shown as either accruals or prepayments in the Consolidated Statement of Financial Position. The Company has no further payment obligation once the contributions have been paid. (b) Bonus plans The Company recognizes a liability and an expense for bonus plans if contractually obligated or if there is a past practice that has created a constructive obligation. Share-based payments The Company operates a number of equity-settled, share-based compensation schemes. The fair value of share-based payments under such schemes is expensed on a straight-line basis over the vesting period, based on the Company's estimate of shares that will eventually vest. Where equity settled transactions are entered into with third party service providers, fair value is determined by reference to the value of the services provided in lieu of payment. The expense is measured based on the services received at the date of receipt of those services and is charged to the Consolidated Statement of Comprehensive Income over the period for which the services are received and a corresponding credit is made to reserves. For other equity-settled transactions fair value is determined using the Black-Scholes model and requires several assumptions and estimates as disclosed in note 16. Provisions Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and the amount can be reliably estimated. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. Assumed contingent obligation related to the business combinations On September 19, 2006, the Company acquired Rhinopharma for a total consideration of £1.52 million payable in ordinary shares. In addition, the Company assumed certain contingent obligations owed by Rhinopharma to Vernalis Pharmaceuticals Limited (“Vernalis”), which was subsequently acquired by Ligand Pharmaceuticals, Inc. (“Ligand”), under an assignment and license agreement (the "assumed contingent consideration") following the sale of IP by Vernalis to Rhinopharma. In October 2018, Vernalis was acquired by, and became a wholly owned subsidiary of, Ligand Pharmaceuticals, Inc., or Ligand). The Company refers to the assignment and license agreement as the Ligand Agreement and now refers to Vernalis as Ligand. Pursuant to the agreement Ligand (i) assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and (ii) granted to the Company an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds. The assumed contingent obligation comprises (a) a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Licensed Product; (b) low to mid-single digit royalties based on the future sales performance of all Licensed Products; and (c) a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how. On the date of acquisition the fair value of the assumed contingent obligation was estimated as the expected value of the milestone payment, royalty payments and sub-license payments, based on an assessment of the probability of success using standard market probabilities for respiratory drug development. The risk-weighted value of the assumed contingent arrangement was then discounted back to its net present value applying an effective interest rate of 12% . The initial fair value of the assumed contingent obligation as of December 31, 2006, was deemed to be insignificant at the date of the acquisition, so it was not recorded. The amount of royalties payable under the agreement is based on the future sales performance of certain products, and so the total amount payable is unlimited. The level of sales that may be achieved under the agreement is difficult to predict and subject to estimate, which is inherently uncertain. The value of this assumed contingent obligation is measured at amortized cost using the effective interest rate method, and is re-measured for changes in estimated cash flows, when the probability of success changes. The assumed contingent obligation is accounted for as a liability, and any adjustments made to the value of the liability will be recognized in the Consolidated Statement of Comprehensive Income for the period. Government and other grants The Company may receive government, regional or charitable grants to support its research efforts in defined projects where these grants provide for reimbursement of approved costs incurred as defined in the respective grants. Income in respect of such grants would include contributions towards the costs of research and development. Income would be recognized when costs under each grant are incurred in accordance with the terms and conditions of the grant and the collectability of the receivable is reasonably assured. Government, regional and charitable grants relating to costs would be deferred and recognized in the Consolidated Statement of Comprehensive Income over the period necessary to match them with the costs they are intended to compensate. When the cash in relation to recognized government, regional or charitable grants is not yet received the amount is included as a receivable on the Consolidated Statement of Financial Position. Where the grant income is directly related to the specific items of expenditure incurred, the income would be netted against such expenditure. Where the grant income is not a specific reimbursement of expenditure incurred, the Company would include such income under "Other income" in the Consolidated Statement of Comprehensive Income. Financial instruments — initial recognition and subsequent measurement The Company classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument. The Company evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified separately as financial assets, financial liabilities or equity instruments. A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. (a) Financial assets, initial recognition and measurement and subsequent measurement All financial assets not recorded at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs. Financial assets carried at fair value through profit or loss are initially recognized at fair value, and transaction costs are expensed in the income statement. The measurement of financial assets depends on their classification. Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less loss allowance. The Company does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income. (b) Financial liabilities, initial recognition and measurement and subsequent measurement Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss. The Company's financial liabilities include trade and other payables and derivative financial instruments. (c) Derivative financial instruments Derivatives are initially recognized at fair value on the date a derivative contract is entered into and are subsequently re-measured at fair value at the end of each reporting date. The Company holds only one type of derivative financial instrument, the warrants, as explained in Note 2.15. The full fair value of the derivative is classified as a non-current liability when the warrants are exercisable in more than 12 months and as a current liability when the warrants are exercisable in less than 12 months. Changes in fair value of a derivative financial liability when related to a financing arrangement are recognized in the Consolidated Statement of Comprehensive Income within Finance income or Finance expense. Fair value gains or losses on derivatives used for non-financing arrangements are recognized in other operating income or expense. Warrants Warrants issued by the Company to investors as part of a share subscription are compound financial instruments where the warrant meets the definition of a financial liability. The financial liability component is initially measured at fair value in the Consolidated Statement of Financial Position. Equity is measured at the residual between the subscription price for the entire instrument and the liability component. The financial liability component is remeasured depending on its classification. Equity is not remeasured. Short Term Investments Short term investments include fixed term deposits held at banks with original maturities of more than three months but less than a year. They are classified as loans and receivables and are measured at amortized cost using the effective interest method. Transaction costs Qualifying transaction costs might be incurred in anticipation of an issuance of equity instruments and may cross reporting periods. The entity defers these costs on the balance sheet until the equity instrument is recognized. Deferred costs are subsequently reclassified as a deduction from equity when the equity instruments are recognized, as the costs are directly attributable to the equity transaction. If the equity instruments are not subsequently issued, the transaction costs are expensed. Any costs not directly attributable to the equity transaction are expensed. Transaction costs that relate to the issue of a compound financial instrument are allocated to the liability and equity components of the instrument in proportion to the allocation of proceeds. Where the liability component is held at fair value through profit or loss, the transaction costs are expensed to the Consolidated Statement of Comprehensive Income. For liabilities held at amortized cost, transaction costs are deducted from the liability and subsequently amortized. The amount of transaction costs accounted for as a deduction from equity in the period is disclosed separately in accordance with International Accounting Standard (“IAS”) 1. Investments in subsidiaries Investments in subsidiaries are shown at cost less any provision for impairment. New standards, amendments and interpretations adopted by the Company The following amendments have been adopted by the Company for the first time for the financial year beginning on or after January 1, 2018: ▪ IFRS 9 "Financial instruments" ▪ IFRS 15 "Revenue from contracts with customers" IFRS 9 had no material impact on the accounting or measurement of any of the financial instruments the Company currently holds. IFRS 15 had no impact on the financial statements of the Company as it is not currently revenue generating. New standards, amendments and interpretations issued but not effective for the financial year beginning January 1, 2018 and not early adopted New standards and amendments to standards and interpretations have been issued but are not yet effective for annual periods beginning after January 1, 2018 (noted below), and have not been adopted in preparing these consolidated financial statements. IFRS 16 "Leases" (effective for annual periods beginning on or after January 1, 2019) IFRS 16 is effective for accounting periods beginning on or after January 1, 2019 and will replace IAS 17 "Leases". It eliminates the classification of leases as either operating leases or finance leases and, instead, introduces a single lessee accounting model. The Group will recognize new assets and liabilities for its operating leases of office leases (see Note 20). The nature of expenses related to those leases will now change because the Group will recognize a depreciation charge for right-of-use assets and interest expense on lease liabilities. Previously, the Group recognized operating lease expense on a straight-line basis over the term of the lease, and recognize assets and liabilities only to the extent that there was a timing difference between actual lease payments and the expense recognized. Instead, the Group will include the payments due under the lease in its lease liability. Based on the information currently available, using the modified retrospective method, the Group estimates that it will recognize additional lease liabilities of £316 thousand and assets of £325 thousand as of January 1, 2019. There will be no material impact on other lines in the financial statements.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments	Financial Instruments Financial Risk Factors The Company's activities have exposed it to a variety of financial risks: market risk (including currency risk and interest rate risk), credit risk, and liquidity risk. The Company's overall risk management program is focused on preservation of capital and the unpredictability of financial markets and has sought to minimize potential adverse effects on the Company's financial performance and position. (a) Currency risk Foreign currency risk reflects the risk that the Company's net assets will be negatively impacted due to fluctuations in exchange rates. The Company has not entered into foreign exchange contracts to hedge against gains or losses from foreign exchange fluctuations. The summary quantitative date about the Company's exposure to currency risk is as follows. Figures are the pounds sterling values of balances in each currency: December 31, 2018 December 31, 2017 USD EUR USD EUR £'000s £'000s £'000s £'000s Cash and cash equivalents 8,470 21 16,806 301 Short term Investments 25,069 — 19,718 — Trade and other payables 4,329 532 276 403 Sensitivity Analysis A reasonably possible strengthening (weakening) of the Euro, U.S. dollar, or pounds sterling against all other currencies as of December 31, 2018 and 2017 would have affected the measurement of the financial instruments denominated in a foreign currency and affected equity and profit and loss by the amounts shown below. This analysis assumes that all other variables remain constant. Profit or loss and equity Strengthening Weakening December 31, 2018 £'000s £'000s EUR (5% movement) (26 ) 26 USD (5% Movement) 1,461 (1,461 ) December 31, 2017 £'000s £'000s EUR (5% movement) 35 (35 ) USD (5% Movement) 1,840 (1,840 ) Foreign currency denominated trade payables are short term in nature (generally 30 to 45 days). The Company has a U.S. operation, the net assets of which are exposed to foreign currency translation risk. (b) Credit risk Credit risk reflects the risk that the Company may be unable to recover contractual receivables. As the Company is still in the development stage no policies are currently required to mitigate this risk. For banks and financial institutions, only independently rated parties with a minimum rating of "B+" are accepted. The Directors recognize that this is an area in which they may need to develop specific policies should the Company become exposed to further financial risks as the business develops. As of December 31, 2018 , and December 31, 2017 , cash and cash equivalents and short term investments were placed at the following banks: Cash and Cash Equivalents Year ended December 31, 2018 Credit rating Year ended December 31, 2017 Credit rating £'000 £'000 Banks Royal Bank of Scotland 150 A1 16,623 A2 Lloyds Bank 15,862 Aa3 13,448 Aa3 Standard Chartered — A1 1,242 A1 Citibank 3,135 A1 — — Barclays 449 A2 — — Wells Fargo 188 Aa1 130 Aa1 Total 19,784 31,443 Short Term Investments Year ended December 31, 2018 Credit Year ended December 31, 2017 Credit £'000 £'000 Banks Royal Bank of Scotland 9,186 A1 15,316 A2 Lloyds Bank 1,567 Aa3 11,036 Aa3 Standard Chartered 15,450 A1 22,467 A1 Citibank 7,053 A1 — — Barclays 11,663 A2 — — Total 44,919 48,819 (c) Management of capital The Company considers capital to be its equity reserves. At the current stage of the Company's life cycle, the Company's objective in managing its capital is to ensure funds raised meet the research and operating requirements until the next development stage of the Company's suite of projects. The Company ensures it is meeting its objectives by reviewing its Key Performance Indicators to ensure the research activities are progressing in line with expectations, costs are controlled and unused funds are placed on deposit to conserve resources and increase returns on surplus cash held. (d) Interest rate risk As of December 31, 2018 , the Company had cash deposits of £19.8 million ( 2017 : £31.4 million ) and short term investments of £44.9 million ( 2017 : £48.8 million). The rates of interest received during 2018 ranged between 0.0% and 2.87% . A 0.25% increase in interest rates would not have a material impact on finance income. The Company's exposure to interest rate risk, which is the risk that the interest received will fluctuate as a result of changes in market interest rates on classes of financial assets and financial liabilities, was as follows: December 31, 2018 December 31, 2017 Floating interest rate Fixed Interest rate Floating interest rate Fixed Interest rate £'000s £'000s £'000s £'000s Financial asset Cash deposits 15,082 4,702 25,720 5,723 Short Term Investments — 44,919 — 48,819 Total 15,082 49,621 25,720 54,542 (e) Liquidity risk The Company prepares periodic working capital forecasts for the foreseeable future, allowing an assessment of the cash requirements of the Company, to manage liquidity risk. The following table provides an analysis of the Company's financial liabilities. The carrying value of all balances is equal to their fair value. The Company's maturity analysis for the derivative financial instrument from the issue of warrants is given in note 17. LESS THAN 1 YEAR BETWEEN 1 AND 2 YEARS BETWEEN 2 AND 5 YEARS OVER 5 YEARS (1) £'000s £'000s £'000s £'000s At December 31, 2018 Trade payables 2,839 — — — Other payables 12 — — — Accruals 4,882 — — — Contingent obligation — — — 1,807 Total 7,733 — — 1,807 (1) This table includes the undiscounted amount of the assumed contingent obligation. See note 19. LESS THAN 1 YEAR BETWEEN 1 AND 2 YEARS BETWEEN 2 AND 5 YEARS OVER 5 YEARS (1) £'000s £'000s £'000s £'000s At December 31, 2017 Trade payables 1,214 — — — Other payables 74 — — — Accruals 5,866 — — — Contingent obligation — — — 1,807 Total 7,154 — — 1,807 (1) This table includes the undiscounted amount of the assumed contingent obligation. See note 19. Fair value estimation The carrying amounts of cash and cash equivalents, receivables, accounts payable and accrued liabilities approximate to fair value due to their short-term nature. The carrying amount of the assumed contingent liability approximates to fair value as the underlying assumptions are currently similar. For financial instruments that are measured in the Consolidated Statement of Financial Position at fair value, IFRS 7 requires disclosure of fair value measurements by level of the following fair value measurement hierarchy: ▪ Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1); ▪ Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly or indirectly (level 2); and ▪ Inputs for the asset or liability that are not based on observable market data (level 3). For the year ended December 31, 2018 , and 2017 , fair value adjustments to financial instruments through profit and loss resulted in the recognition of finance loss of £1.2 million in 2018 and a finance income of £6.7 million in 2017. The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available and rely as little as possible on entity specific estimates. If all significant inputs required to ascertain the fair value of an instrument are observable, the instrument is included in level 2. If one or more of the significant inputs are not based on observable market data, the instrument is included in level 3. Level 3 Total £'000s £'000s At December 31, 2018 Derivative financial instrument 2,492 2,492 Total 2,492 2,492 Movements in Level 3 items during the years ended December 31, 2018 , and 2017 are as follows: Derivative financial instrument 2018 2017 £'000s £'000s At January 1 1,273 7,923 Fair value adjustments recognized in profit and loss 1,219 (6,650 ) At December 31 2,492 1,273 Further details relating to the derivative financial instrument are set out in notes 4 and 17 of these financial statements. In determining the fair value of the derivative financial instrument, the Company applied the Black Scholes model; key inputs include the share price at reporting date, estimations on timelines, volatility and risk-free rates. These assumptions and the impact of changes in these assumptions, where material, are disclosed in note 17. Change in liabilities arising from financing activities The Company has provided a reconciliation so that changes in liabilities arising from financing activities, including both changes arising from cash flows and non-cash changes can be evaluated. 2018 Derivative financial instrument £'000s At January 1 1,273 Fair value adjustments - non cash 1,219 At December 31 2,492 See note 17 for information relating to the derivative financial instrument.

Critical accounting estimates a

Critical accounting estimates and judgments	12 Months Ended
	Dec. 31, 2018
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract]
Critical accounting estimates and judgments	Critical accounting estimates and judgments The preparation of financial statements in conformity with IFRS requires the use of accounting estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Although these estimates are based on management's best knowledge of current events and actions, actual results ultimately may differ from those estimates. IFRS also requires management to exercise its judgment in the process of applying the Company's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are as follows: (a) Assumed contingent obligation The Company has a material obligation for the future payment of royalties and milestones associated with contractual obligations on ensifentrine, a development product acquired as part of the acquisition of Rhinopharma. The estimation of the fair value of the assumed contingent obligation on acquisition requires the selection of an appropriate valuation model, consideration as to the inputs necessary for the valuation model chosen, the estimation of the likelihood that the regulatory approval milestone will be achieved and estimates of the future cash flows and their timing (for further detail see note 17). The estimates for the assumed contingent obligation are based on a discounted cash flow model. Key estimates included in the fair value calculation of deferred consideration are: ▪ development, regulatory and marketing risks associated with progressing the product to market approval in key target territories; ▪ market size and product acceptance by clinicians, patients and reimbursement bodies; ▪ gross and net selling price; ▪ costs of manufacturing, product distribution and marketing support; ▪ launch of competitive products; and ▪ discount rate and time to crystallization of contingent consideration. When there is a change in the expected cash flows, the assumed contingent obligation is re-measured with the change in value going through the Consolidated Statement of Comprehensive Income. Cash flow estimates are revised when the probability of success changes. The assumed contingent obligation is measured at amortized cost with the discount unwinding in the Consolidated Statement of Comprehensive Income throughout the year. Actual outcomes could differ significantly from the estimates made. The value of the assumed contingent obligation as of December 31, 2018 amounted to £1.0 million . ( 2017 : £0.9 million ). The increase in value of the assumed contingent obligation during 2018 amounted to £0.1 million ( 2017 : £ 0.1 million ) and the movement relates to unwinding the discount on the liability and retranslating for changes in U.S. dollar exchange rates. The expense relating to the unwinding of the discount was recorded in finance expense. There was no change in the year to the probability of success and consequently cash flow estimates were not revised. The discount percentage applied is 12% . (b) Valuation of the July 2016 warrants Pursuant to the July 2016 Placement, the Company issued 31,115,926 units to new and existing investors at the placing price of £1.4365 per unit. Each unit comprises one ordinary share and one warrant. The warrants entitle the investors to subscribe for in aggregate a maximum of 12,401,262 ordinary shares. In accordance with IAS 32 and the Company’s accounting policy, as disclosed in note 2.15, the Company classified the warrants as a derivative financial liability to be presented on the Company's Consolidated Statement of Financial Position. The fair value of these warrants is determined by applying the Black-Scholes model. Assumptions are made on inputs such as time to maturity, the share price, volatility and risk free rate in order to determine the fair value per warrant. For further details see note 17. (c) Recognition of research and development expenditure The Company incurs research and development expenditure from third parties. The Company recognizes this expenditure in line with the management’s best estimation of the stage of completion of each research and development project. This includes the calculation of accrued costs at each period end to account for expenditure that has been incurred. This requires management to estimate full costs to complete for each project and also to estimate its current stage of completion. Costs relating to clinical research organization expenses in the year were £14.0 million . The related accruals and prepayments were £3.4 million and £0.7 million , respectively. (d) Transaction costs related to the Global Offering In 2017, the Company incurred various transaction costs relating to the Global Offering, including commissions, professional advisor fees, financial advice, listing fees and other costs. When management judged them to be incremental costs directly attributable to the transaction they were accounted for as a deduction from equity. Otherwise the costs were expensed to the Consolidated Income Statement as incurred.

Earnings per share

Earnings per share	12 Months Ended
	Dec. 31, 2018
Disclosure of earnings per share [Abstract]
Earnings per share	Earnings per share Basic loss per ordinary share of 18.9p ( 2017 : 23.4p and 2016 : 15.0 p) for the Company is calculated by dividing the loss for the year ended December 31, 2018 by the weighted average number of ordinary shares in issue of 105,110,504 as of December 31, 2018 ( 2017 : 87,748,031 and 2016 : 33,499,413 ). Potential ordinary shares are not treated as dilutive as the entity is loss making and such shares would be anti-dilutive.

Segmental reporting

Segmental reporting	12 Months Ended
	Dec. 31, 2018
Disclosure of entity's operating segments [Abstract]
Segmental reporting	Segmental reporting The Company’s activities are covered by one operating and reporting segment: Drug Development. There have been no changes to management’s assessment of the operating and reporting segment of the Company during the year. All non-current assets are based in the United Kingdom.

Operating loss

Operating loss	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Operating loss	Operating loss Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Operating Loss is stated after charging / (crediting): Research and development costs: Employee benefits (note 8) 3,360 3,435 2,037 Amortization of patents (note 12) 85 111 51 Legal, professional consulting and listing fees 161 331 — Other research and development expenses 15,688 19,840 2,434 Total research and development costs 19,294 23,717 4,522 General and administrative costs: Employee benefits (note 8) 3,240 2,857 865 Legal, professional consulting and listing fees 1,296 2,045 884 Amortization of computer software (note 12) 5 5 1 Loss on disposal of property, plant and equipment (note 13) — — 3 Depreciation of property, plant and equipment (note 13) 8 7 10 Operating lease charge — land and buildings 384 294 169 (Gain) / Loss on variations in foreign exchange rate (9 ) 36 139 Other general and administrative expenses 1,373 795 427 Total general and administrative costs 6,297 6,039 2,498 Operating loss 25,591 29,756 7,020

Directors' emoluments and staff

Directors' emoluments and staff costs	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Directors' emoluments and staff costs	Directors' emoluments and staff costs Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 The average number of employees (excluding directors) of the Company during the year: Research and Development 7 7 5 General and Administrative 7 5 2 Total 14 12 7 Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Aggregate emoluments of directors: Salaries and other short-term employee benefits 830 897 951 Social security costs 94 103 118 Incremental payment for additional services 27 — 44 Other pension costs 10 17 19 Total directors' emoluments 961 1,017 1,132 Share-based payment charge 1,337 1,037 257 Directors' emoluments including share-based payment charge 2,298 2,054 1,389 Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Aggregate executive officers costs: Wages and salaries 857 864 512 Social security costs 83 81 22 Incremental payment for additional services — — — Share-based payment charge 769 1,332 235 Other pension costs 19 17 2 Total executive officers costs 1,728 2,294 771 Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Aggregate other staff costs: Wages and salaries 1,622 1,272 515 Social security costs 150 101 76 Incremental payment for additional services — — 58 Share-based payment charge 795 550 84 Other pension costs 34 21 9 Total other staff costs 2,601 1,944 742 The Company considers key management personnel to comprise directors and executive officers. The Company operates a defined contribution pension scheme for U.K. employees and executive directors. The total pension cost during the year ended December 31, 2018 was £63 thousand ( 2017 : £55 thousand and 2016 : £ 30 thousand ). There were no prepaid or accrued contributions to the scheme at December 31, 2018 ( 2017 and 2016 : £ nil ).

Finance income and expense

Finance income and expense	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Finance income and expense	Finance income and expense Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Finance income: Interest received on cash balances 861 345 86 Foreign exchange gain on translating foreign currency denominated balances 1,922 — 687 Fair value adjustment on derivative financial instruments (note 17) — 6,650 1,068 Other Income — 23 — Total finance income 2,783 7,018 1,841 Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Finance expense: Fair value adjustment on derivative financial instruments (note 17) 1,219 — — Transaction costs allocated to the issue of warrants (note 17) — — 586 Foreign exchange loss on translating foreign currency denominated balances — 2,392 — Remeasurement of assumed contingent arrangement — — 122 Unwinding of discount factor related to the assumed contingent arrangement (note 19) 106 73 86 Total finance expense 1,325 2,465 794

Taxation

Taxation	12 Months Ended
	Dec. 31, 2018
Disclosure of income tax [Abstract]
Taxation	Taxation Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Analysis of tax credit for the year Current tax: U.K. tax credit (4,290 ) (5,006 ) (1,067 ) U.S. tax charge 30 306 129 Adjustment in respect of prior periods 28 (6 ) (16 ) Total tax credit (4,232 ) (4,706 ) (954 ) The difference between the total tax shown above and the amount calculated by applying the standard rate of tax to the loss before tax is as follows: Factors affecting the tax credit for the year Loss on ordinary activities before taxation (24,133 ) (25,203 ) (5,973 ) Multiplied by standard rate of corporation tax of 19% (2017: 19.25% and 2016: 20%) (4,585 ) (4,852 ) (1,195 ) Effects of: Non-deductible expenses 540 675 292 Fair value adjustment on derivative financial instruments 232 (1,280 ) (214 ) Research and development incentive (1,846 ) (2,116 ) (427 ) Temporary differences not recognized (3 ) (2 ) (4 ) Difference in overseas tax rates 8 136 56 Tax losses carried forward not recognized 1,394 2,739 554 Adjustment in respect of prior periods 28 (6 ) (16 ) Total tax credit (4,232 ) (4,706 ) (954 ) U.K. corporation tax is charged at 19% ( 2017 : 19.25% and 2016 : 20.00% ) and U.S. federal and state tax at 27.6% ( 2017 and 2016 : 35% ). The following tables represent deferred tax balances recognized in the Consolidated Statement of Financial Position. There were no movements in either the deferred tax asset or the deferred tax liability. As at December 31, 2018 As at December 31, 2017 £'000s £'000s Deferred tax assets 250 250 Deferred tax liabilities (250 ) (250 ) Net balances — — The deferred tax liability relates to the difference between the accounting and tax bases of the IP R&D intangible asset. A deferred tax asset relating to UK tax losses has been recognized and offset against the liability. Factors that may affect future tax charges The Company has U.K. tax losses available for offset against future profits in the United Kingdom. However an additional deferred tax asset has not been recognized in respect of such items due to uncertainty of future profit streams. As of December 31, 2018 , the unrecognized deferred tax asset at 17% is estimated to be £6.65 million ( 2017 : £5.43 million at 17% ).

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about intangible assets [abstract]
Goodwill	Goodwill As of December 31, 2018 As of December 31, 2017 £'000s £'000s Goodwill at January 1 and December 31 441 441 Goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the acquisition of Rhinopharma in September 2006. Goodwill is not amortized, but is tested annually for impairment. Recognizing that the Company is still in its pre-revenue phase and that the research projects are not yet ready for commercial use, the Company assesses the recoverable amount of the CGU containing the IP R&D and goodwill with reference to the Company's market capitalization as of December 31, 2018 , the date of testing of IP R&D and goodwill impairment. The market capitalization of the Company was approximately £92.2 million as of December 31, 2018, ( 2017 : £109.7 million ) compared to the Company's net assets of £62.9 million ( 2017 : £79.9 million ). Therefore, no impairment was recognized.

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about intangible assets [abstract]
Intangible assets	Intangible assets IP R&D Computer software Patents Total £'000s £'000s £'000s £'000s Cost At January 1, 2017 1,469 6 592 2,067 Additions — 5 203 208 Disposals — — (68 ) (68 ) At December 31, 2017 1,469 11 727 2,207 Accumulated amortization At January 1, 2017 — 1 189 190 Charge for year — 5 111 116 Disposals — — (68 ) (68 ) At December 31, 2017 — 6 232 238 Net book value At December 31, 2017 1,469 5 495 1,969 IP R&D Computer software Patents Total £'000s £'000s £'000s £'000s Cost At January 1, 2018 1,469 11 727 2,207 Additions — 4 251 255 Disposals — — (6 ) (6 ) At December 31, 2018 1,469 15 972 2,456 Accumulated amortization At January 1, 2018 — 6 232 238 Charge for year — 5 85 90 Disposals — — (6 ) (6 ) At December 31, 2018 — 11 311 322 Net book value At December 31, 2018 1,469 4 661 2,134 Intangible assets comprise patents, computer software and an IP R&D asset that arose on the acquisition of Rhinopharma and investment in patents to protect ensifentrine. IP R&D is currently not amortized and is reviewed for impairment on an annual basis, together with goodwill, or where there is an indication that the assets might be impaired until the asset is brought into use. Patents are amortized over a period of ten years and are regularly reviewed for impairment to ensure the carrying amount exceeds the recoverable amount in accordance with note 2.8. Recognizing that the Company is still in its pre-revenue phase and that the research projects are not yet ready for commercial use, the Company assesses the recoverable amount of the CGU containing the IP R&D and goodwill with reference to the Company's market capitalization as of December 31, 2018 , the date of testing of IP R&D and goodwill impairment. The market capitalization of the Company was approximately £92.2 million as of December 31, 2018, ( 2017 : £109.7 million) compared to the Company's net assets of £62.9 million ( 2017 : £79.9 million). Therefore, no impairment was recognized. The Company notes that after the reduction in the share price since December 31, 2018, and as at February 21, 2019, the market value of the Company was £6.6 million less than the net book value as of 31 December 2018. The Company judges that the decline in the share price was a reaction to recent clinical trial results and was driven by relatively low trading volumes. The Company believes that the trial data was encouraging and notes that this has not resulted in a significant change in development plans, timelines, potential market share or pricing.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [abstract]
Property, plant and equipment	Property, plant and equipment Computer hardware Total £'000s £'000s Cost At January 1, 2017 17 17 Additions 9 9 At December 31, 2017 26 26 Accumulated depreciation At January 1, 2017 3 3 Charge for the year 7 7 At December 31, 2017 10 10 Net book value At December 31, 2017 16 16 Computer hardware Total £'000s £'000s Cost At January 1, 2018 26 26 Additions 13 13 At December 31, 2018 39 39 Accumulated depreciation At January 1, 2018 10 10 Charge for the year 8 8 At December 31, 2018 18 18 Net book value At December 31, 2018 21 21

Prepayments and other receivabl

Prepayments and other receivables	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Prepayments and other receivables	Prepayments and other receivables As of December 31, 2018 As of December 31, 2017 £'000s £'000s Prepayments 1,362 1,138 Other receivables 1,101 672 Total prepayments and other receivables 2,463 1,810 The prepayments balance includes prepayments for insurance and clinical activities.

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2018
Disclosure of share capital, reserves and other equity interest [Abstract]
Share Capital	Share Capital The movements in the Company's share capital are summarized below: Date Description Number of shares Share Capital amounts in £'000s January 1, 2017 51,361,063 2,568 May 2, 2017 Issuance of shares 47,653,100 2,383 May 18, 2017 Issuance of shares 5,539,080 277 May 26, 2017 Issuance of shares 330,824 17 September 13, 2017 Exercise of options 133,333 6 As at December 31, 2017 105,017,400 5,251 August 9, 2018 Vesting of RSUs 58,112 3 September 20, 2018 Vesting of RSUs 251,125 12 As at December 31, 2018 105,326,637 5,266 The total number of authorized ordinary shares, with a nominal value of £0.05 each, is 200,000,000 (share capital of £10,000,000 ). All 105,326,637 ordinary shares at December 31, 2018 are allotted, unrestricted, called up and fully paid. As at December 31, 2018 , the number of ordinary shares in issue was 105,326,637 . All new ordinary shares rank pari passu with existing ordinary shares. During 2018, the Company issued 309,237 ordinary shares upon vesting of employee restricted share units. On April 26, 2017, the Company announced the closing of the Global Offering of an aggregate of 47,399,001 new ordinary shares, comprising 5,768,000 ADSs at a price of $ 13.50 per ADS and 1,255,001 ordinary shares at a price of £ 1.32 per ordinary share. During May 2017, the underwriters purchased an additional 733,738 ADSs, representing 5,869,904 ordinary shares, at a price of $ 13.50 per ADS. The total gross proceeds in the Global Offering amounted to $ 89.9 million (£ 70.0 million). In addition, the Chairman of Verona Pharma’s board of directors, Dr. David Ebsworth, and an existing shareholder agreed to subscribe for 254,099 new ordinary shares at a price of £ 1.32 per ordinary share in the Shareholder Private Placement, contingent on and concurrent with the Global Offering and generating gross proceeds of £ 0.3 million. Where there is a time and foreign exchange difference between proceeds from a share issue becoming due and being received, the movement is taken to Finance income or Finance expense as appropriate. In respect of the Global Offering and Shareholder Private Placement, the Company recorded a finance expense of £ 439 thousand arising from movements in exchange rates on funds receivable, offset by a saving on commission payable of £31 thousand, for a net finance expense of £ 408 thousand. On September 13, 2017, the company issued 133,333 new shares upon exercise of share options at 110 p per share, resulting in proceeds of £147 thousand to the Company. On February 8, 2017, the board of directors of the Company approved a share consolidation where every 50 existing ordinary shares of £0.001 were consolidated into one ordinary share of £0.05 .

Share-based payments charge

Share-based payments charge	12 Months Ended
	Dec. 31, 2018
Disclosure of share-based payment arrangements [Abstract]
Share-based payments charge	Share-based payments charge In accordance with IFRS 2 "Share Based Payments," the cost of equity-settled transactions is measured by reference to their fair value at the date at which they are granted. Where equity-settled transactions were entered into with third party service providers, fair value is determined by reference to the value of the services provided. For other equity-settled transactions fair value is determined using the Black-Scholes model. The cost of equity-settled transactions is recognized over the period until the award vests. No expense is recognized for awards that do not ultimately vest. At each reporting date, the cumulative expense recognized for equity-based transactions reflects the extent to which the vesting period has expired and the number of awards that, in the opinion of the Directors at that date, will ultimately vest. The costs of equity-settled share-based payments to employees are recognized in the Statement of Comprehensive Income, together with a corresponding increase in equity during the vesting period. During the twelve months ended December 31, 2018 , the Company recognized a share-based payment expense of £ 2.90 million ( 2017 : £ 2.92 million ). The charge is included within both general and administrative costs as well as in research and development costs and represents the current year's allocation of the expense for relevant share options. The Company granted share options under an Unapproved Share Option Scheme (the "Unapproved Scheme"). Under the Unapproved Scheme, options were granted to employees, directors and consultants to acquire shares at a price to be determined by the Directors. In general, options granted prior to December 31, 2016 were granted at a premium to the share price at the date of grant and vested over a period of three years from the date of grant, one third vesting on the first anniversary of grant, a further third vesting on the second anniversary of grant and the remainder vesting on the third anniversary of grant. Options granted since January 1, 2017 generally vest over three or four years from the date of the grant using two different methods. The first method is one third vesting over one year , the second third vesting over two years and the final third vesting over three years . The second method is one quarter vesting over one year , the second quarter vesting over two years , the third quarter vesting over three years and the final quarter vesting over four years. The vesting period is defined as the period between the date of grant and the date when the options become exercisable. The options are exercisable during a period ending ten years after the date of grant. Options were issued to advisors under the Unapproved Scheme. Such options generally vested immediately and were exercisable between one and two years after grant. In 2016, the Company issued options under its tax efficient EMI Option Scheme (the "EMI Scheme"). Under the EMI Scheme, options were granted to employees and directors who were contracted to work at least 25 hours a week for the Company or for at least 75% of their working time. The options granted under the EMI Scheme are exercisable at a price that is above the share price at the date of the grant and in accordance with a vesting schedule determined by the Directors at the time of grant and have an exercise period of ten years from the date of grant. Under its 2017 Incentive Award Plan, the Company grants RSUs to employees and directors. The RSUs vest over a period of three or four years from the date of the grant using two different methods. The first method is one third vesting over one year , the second third vesting over two years and the final third vesting over three years . The second method is one quarter vesting over one year, the second quarter vesting over two years , the third quarter vesting over three years and the final quarter vesting over four years. In the year ended December 31, 2018 , under the 2017 Incentive Award Plan, the Company granted 2,090,847 ( 2017 : 4,656,828 ) share options and 273,390 RSUs ( 2017 : 1,052,236 ). The total fair values of the options and RSUs were estimated using the Black-Scholes option-pricing model for equity-settled transactions and amounted to £ 2.32 million ( 2017 : £ 5.33 million ). The cost is amortized over the vesting period of the options and RSUs on a straight-line basis. The following assumptions were used for the Black-Scholes valuation of share options and RSUs granted in 2017 and 2018 . For the options granted under the Unapproved Scheme the table indicates the ranges used in determining the fair-market values, aligning with the various dates of the underlying grants. The volatility is calculated using historic weekly averages of the Company's share price over a period that is in line with the expected life of the options and RSUs. Issued in 2017 Unapproved Restricted Stock Units Options granted 4,656,828 1,052,236 Risk-free interest rate 0.29% - 0.62% 0.42%-0.62% Expected life of options 5.5 – 7.0 years 5.5 – 7.0 years Annualized volatility 71.3% - 73.3% 71.3% - 73.3% Dividend rate 0.00 % 0.00 % Vesting period 1 to 4 years 1 to 4 years Issued in 2018 Unapproved Restricted Stock Units Options granted 2,090,847 273,390 Risk-free interest rate 1.08% - 1.22% 1.08% - 1.22% Expected life of options 5.5 - 7 years 5.5 - 7 years Annualized volatility 69.88% -71.35% 69.88% -71.35% Dividend rate 0.00 % 0.00 % Vesting period 1 to 4 years 1 to 4 years The Company had the following share options movements in the year ended December 31, 2018 : Year of issue Exercise At January 1, 2018 Options granted Options forfeited Options expired At December 31, 2018 Expiry date 2012 2.50 - 7.50 99,993 — — — 99,993 June 1, 2022 2013 2 99,990 — — — 99,990 April 15, 2023 2013 2.00 159,999 — — — 159,999 July 29, 2023 2014 1.75 109,998 — — — 109,998 May 15, 2024 2014 1.75 49,998 — — — 49,998 May 15, 2024 * 2014 1.10 - 1.75 66,667 — — (66,667 ) — August 6, 2018 ** 2015 1.25 41,997 — — — 41,997 January 29, 2025 * 2015 1.25 549,999 — — — 549,999 January 29, 2025 2016 2 260,000 — (20,000 ) — 240,000 February 2, 2026 2016 2.00 21,996 — — — 21,996 February 2, 2026 * 2016 1.80 809,996 — (133,332 ) — 676,664 August 3, 2026 2016 1.89 299,997 — — — 299,997 September 13, 2026 2016 2.04 300,000 — — — 300,000 September 16, 2026 2017 1.32 - 1.525 4,656,828 — (563,664 ) — 4,093,164 April 26, 2027 2018 1.46 — 2,090,847 (82,528 ) — 2,008,319 March 8, 2028 Total 7,527,458 2,090,847 (799,524 ) (66,667 ) 8,752,114 * Options granted under the EMI Scheme. * * Valued based on fair value of services received. The Company had the following RSU movements in the year ended December 31, 2018 : Year of issue Exercise At January 1, 2018 Units Units Units At December 31, 2018 Expiry date 2017 n/a 1,052,236 — (309,237 ) (13,012 ) 729,987 April 26, 2027 2018 n/a — 273,390 — (140,904 ) 132,486 March 8, 2028 Total 1,052,236 273,390 (309,237 ) (153,916 ) 862,473 Outstanding and exercisable share options by scheme as of December 31, 2018 : Plan Outstanding Exercisable Weighted average exercise price in £ for Outstanding Weighted average exercise price in £ for Exercisable Unapproved 8,538,130 3,336,232 1.49 1.57 EMI 213,984 206,652 3.06 3.09 Total 8,752,114 3,542,884 1.53 1.66 As of December 31, 2018 there were no restricted share options exercisable ( 2017 : nil ) and there is no exercise price for restricted share options. The options outstanding at December 31, 2018 had a weighted average remaining contractual life of 8 years ( 2017 : 8.6 years ). For 2017 and 2018 , the number of options granted and expired and the weighted average exercise price of options were as follows: Number of options Weighted average exercise price (£) At January 1, 2017 3,037,296 1.87 Options granted in 2017: Employees 3,150,846 1.32 Directors 1,505,982 1.32 Options exercised in the year (133,333 ) 1.10 Options expired in the year (33,333 ) 1.90 At December 31, 2017 7,527,458 1.53 Exercisable at December 31, 2017 797,333 2.04 Number of options Weighted average exercise price (£) At January 1, 2018 7,527,458 1.53 Options granted in 2018: Employees 1,222,089 1.46 Directors 868,758 1.46 Options forfeited in the year (799,524 ) 1.43 Options expired in the year (66,667 ) 1.75 At December 31, 2018 8,752,114 1.53 Exercisable at December 31, 2018 3,542,884 1.66 The following table shows the number of RSUs issued in 2017. There were no RSUs forfeited, canceled or vested in 2017. The fair value of each unvested RSU at grant date was £1.32 . Number of At January 1, 2017 — Granted: Employees 705,841 Directors 346,395 At December 31, 2017 1,052,236 The following table shows the number of RSUs issued, exercised and forfeited in 2018. The fair value of each unvested RSU granted in 2018 was £1.46 . Number of At January 1, 2018 1,052,236 Granted: Employees 136,404 Directors 136,986 RSUs vested in the year (309,237 ) RSUs forfeited in the year (153,916 ) At December 31, 2018 862,473

Trade and other payables

Trade and other payables	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Trade and other payables	Trade and other payables As of December 31, 2018 As of December 31, 2017 £'000s £'000s Trade payables 2,839 1,214 Other payables 12 74 Accruals 4,882 5,866 Total trade and other payables 7,733 7,154

Assumed contingent obligation r

Assumed contingent obligation related to the business combination	12 Months Ended
	Dec. 31, 2018
Disclosure of other provisions, contingent liabilities and contingent assets [Abstract]
Assumed contingent obligation related to the business combination	Assumed contingent obligation related to the business combination The value of the assumed contingent obligation as of December 31, 2018 amounts to £996 thousand ( 2017 : £875 thousand ). The increase in value of the assumed contingent obligation during 2018 amounted to £121 thousand ( 2017 : £73 thousand ) and the unwinding of the discount on the liability was recorded in finance expense. Periodic re-measurement is triggered by changes in the probability of success. The discount percentage applied is 12% . In 2018 there were no events that triggered remeasurement. 2018 2017 £'000s £'000s January 1, 2018 875 802 Impact of changes in foreign exchange rates 15 (23 ) Unwinding of discount factor 106 96 December 31, 2018 996 875 For the amount recognized December 31, 2018 of £121 thousand ( 2017 : £73 thousand ) the effect if underlying assumptions were to deviate up or down is presented in the following table (assuming the probability of success does not change): Discount rate (up / down 1 % pt) Revenue (up / down 10 % pts) £'000s £'000s Variable up 954 1,026 Base case, reported fair value 996 996 Variable down 1,040 966

Warrants

Warrants	12 Months Ended
	Dec. 31, 2018
Disclosure of share capital, reserves and other equity interest [Abstract]
Warrants	Derivative financial instrument Pursuant to the July 2016 Placement, on July 29, 2016, the Company issued 31,115,926 units to new and existing investors at the placing price of £1.4365 per unit. Each unit comprises one ordinary share and one warrant. The warrant holders can subscribe for 0.4 of an ordinary share at a per share exercise price of 120% of the placing price or £ 1.7238 . The warrant holders can opt for a cashless exercise of their warrants, whereby the warrant holders can choose to exchange the warrants held for reduced number of warrants exercisable at nil consideration. The reduced number of warrants is calculated based on a formula considering the share price and the exercise price of the warrants. The warrants are therefore classified as a derivative financial liability, since their exercise could result in a variable number of shares to be issued. The warrants entitled the investors to subscribe for in aggregate a maximum of 12,401,262 shares. The warrants can be exercised on the "Commencement Date" which is defined as the earlier of the consummation of the Global Offering (being May 2, 2017) or the first anniversary of the grant, and the exercise period shall end on the fifth anniversary of the commencement date (being May 2, 2022). The ordinary shares and warrants were accounted for as a compound financial instrument. The warrants component of the instrument issued at the July 2016 Placement was classified as a derivative financial liability and was initially measured at fair value of £9.0 million . The residual amount of proceeds totaling £35.7 million was recognized within equity. Subsequently the financial liability was re-measured at the reporting date at fair value through profit or loss. The total of transaction costs the Company incurred for the above transactions amounted to £2.9 million of which £0.6 million was allocated to the warrants and the remaining £2.3 million was presented as a reduction to share premium, by reference to the proceeds allocated to each component. The amount assigned to the financial liability of the warrants was subsequently presented as finance expense in the Consolidated Statement of Comprehensive Income. In the year ended December 31, 2018 , no warrants were forfeited ( 2017 : 45,108 ). The table below presents the assumptions in applying the Black-Scholes model to determine the fair value of the warrants. As of December 31, 2018 As of December 31, 2017 Shares available to be issued under warrants 12,401,262 12,401,262 Exercise price £ 1.7238 £ 1.7238 Risk-free interest rate 0.760 % 0.420 % Expected term to exercise 3.40 years 1.79 years Annualized volatility 60.72 % 47.35 % Dividend rate 0.00 % 0.00 % The figures disclosed above relating to the issue of the shares and warrants have been retrospectively adjusted to reflect the 50 -for- 1 share consolidation in 2017 as described in note 1. The original number of units issued to new and existing investors was 1,555,796,345 units at a placing price of 2.873 pence per unit and an exercise price of 3.4476 pence per share. This entitled the investors to subscribe for in aggregate a maximum of 622,318,538 shares. As per the reporting date, the Company updated the underlying assumptions and calculated a fair value of these warrants amounting to £2.5 million . The variance of 1.2 million is recorded as finance expense in the Consolidated Statement of Comprehensive Income. Derivative financial instrument Derivative financial instrument 2018 2017 £'000s £'000s At January 1 1,273 7,923 Fair value adjustments recognized in profit or loss 1,219 (6,650 ) At December 31 2,492 1,273 For the amount recognized at December 31, 2018 , the effect when the following parameter deviates up or down is presented in the below table. Volatility (up / down 10% pts) £'000s Variable up 3,262 Base case, reported fair value 2,492 Variable down 1,738

Financial commitments

Financial commitments	12 Months Ended
	Dec. 31, 2018
Disclosure of leases [Abstract]
Financial commitments	Financial commitments As of December 31, 2018 , and 2017, the Company was committed to making the following payments under non-cancellable operating leases related to its facilities. Land and Buildings Land and Buildings 2018 2017 £'000s £'000s Operating lease obligations: Within one year 572 291 Between one and five years 28 277 Total 600 568

Related parties transactions an

Related parties transactions and other shareholder matters	12 Months Ended
	Dec. 31, 2018
Disclosure of related party [Abstract]
Related parties transactions and other shareholder matters	Related parties transactions and other shareholder matters (i) Related party transactions The Directors have authority and responsibility for planning, directing and controlling the activities of the Company and they therefore comprise key management personnel as defined by IAS 24, ("Related Party Disclosures"). (ii) Other shareholder matters The Company has entered into the following arrangements with parties who are significant shareholders of the Company, though they are not classed as related parties. The Company entered into relationship agreements with Vivo Ventures Fund VII, L.P., Vivo Ventures VII Affiliates Fund, L.P., Vivo Ventures Fund VI, L.P., Vivo Ventures VI Affiliates Fund, L.P. (collectively, "Vivo Capital"), Orbimed Private Investments VI L.P. ("Orbimed"), Abingworth Bioventures VI L.P. ("Abingworth"), and Arix Bioscience plc ("Arix") and Arthurian Life Sciences SPV GP Limited, ("Arthurian"). As agreed in these relationship agreements, the above parties invested in the Company as part of the July 2016 Placement, and the Company agreed to appoint representatives designated by Vivo Capital, OrbiMed, Abingworth, and Arix and Arthurian, to the board of directors, who are Dr. Mahendra Shah, Mr. Rishi Gupta, and Dr. Andrew Sinclair and who was, prior to the termination of the appointment rights in the Arix and Arthurian relationship agreement described below, Dr. Ken Cunningham, respectively. The appointment rights within the relationship agreement with Arix and Arthurian terminated on closing of the Global Offering on April 26, 2017. Dr Cunningham agreed to continue to serve on the Company's board of directors as an independent director. The respective appointment rights under the remaining relationship agreements will automatically terminate upon (i) Vivo Capital, OrbiMed or Abingworth (or any of their associates), as applicable, ceasing to beneficially hold 6.5% of the issued ordinary shares, or (ii) the ordinary shares ceasing to be admitted to AIM. The Company also entered into a management rights agreement with Novo A/S under which Novo A/S was entitled to appoint an observer to the Board. The appointment rights within the management rights agreement terminated on closing of the Global Offering on April 26, 2017. Dr. Jan-Anders Karlsson, Chief Executive Officer of the Company, purchased 3,250 ordinary shares for £5 thousand from the market in the year ended December 31, 2018 (2017: £nil). Dr. David Ebsworth, Chairman of the Company, purchased 12,000 ordinary shares for £14 thousand from the market in the year ended December 31, 2018 (2017: £28 thousand). During the year ended December 31, 2017, Vikas Sinha, a Non-Executive Director, purchased of £234 thousand of our ordinary shares, in the form of ADSs, as part of the Global Offering. At December 31, 2018, there was a receivable of £126 thousand (2017: nil ) due from one director and two key management personnel relating to tax due on RSUs that vested in the year ended December 31, 2018. This receivable was repaid, together with interest at a rate of 3.9% per annum, by March 6, 2019. In the year ended December 31, 2018 , a director provided consultancy services for £26 thousand (2017: £nil).

Accounting policies (Policies)

Accounting policies (Policies)	12 Months Ended
	Dec. 31, 2018
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract]
Going concern	Going concern During the year ended December 31, 2018 , the Company had a loss of £19.9 million ( 2017 : £20.5 million ). As of December 31, 2018 , the Company had net assets of £62.9 million ( 2017 : £79.9 million ) of which £64.7 million ( 2017 : £80.3 million) was cash and cash equivalents and short term investments. The operation of the Company is currently being financed from funds that the Company raised from share placings. In April and May 2017, the Company raised $90.3 million ( £70.3 million ) from the Global Offering and the Shareholder Private Placement. On July 29, 2016, the Company raised gross proceeds of £44.7 million from a placing, subscription and open offer (the "July 2016 Placement"). These funds are being used primarily to support the development of ensifentrine in chronic obstructive pulmonary disease ("COPD") and other chronic respiratory diseases, as well as corporate and general administrative expenditures. The Directors believe that the Company has sufficient funds to complete the current clinical trials, to cover corporate and general administration costs and for it to comply with all commitments for at least 12 months from the end of the reporting date and, accordingly, are satisfied that the going concern basis remains appropriate for the preparation of these consolidated financial statements.
Business combination	Business combination The Company applies the acquisition method to account for business combinations. The consideration transferred for the acquisition of a subsidiary is the fair value of the assets transferred, the liabilities incurred to the former owners of the acquiree and the equity interests issued by the Company. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement and the fair value of any pre-existing equity interest in the subsidiary. The excess of the cost of acquisition over the fair value of the Company's share of the identifiable net assets acquired is recorded as goodwill. Goodwill arising on acquisitions is capitalized and is subject to an impairment review, both annually and when there are indications that the carrying value may not be recoverable. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date. Acquisition-related costs are expensed as incurred and included in administrative expenses.
Basis of consolidation	Basis of consolidation These consolidated financial statements include the financial statements of Verona Pharma plc and its wholly owned subsidiaries Verona Pharma, Inc. and Rhinopharma. The acquisition method of accounting was used to account for the acquisition of Rhinopharma. Inter-company transactions, balances and unrealized gains on transactions between group companies are eliminated. Verona Pharma Inc. and Rhinopharma adopt the same accounting policies as the Company.
Foreign currency translation	Foreign currency translation Items included in the Company's consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates ("the functional currency"). The consolidated financial statements are presented in pounds sterling ("£"), which is the functional and presentational currency of the Company. Transactions in foreign currencies are recorded using the rate of exchange ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the rate of exchange ruling at the balance sheet date and the gains or losses on translation are included in the Consolidated Statement of Comprehensive Income. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the original transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The assets and liabilities of foreign operations are translated into pounds sterling at the rate of exchange ruling at the balance sheet date. Income and expenses are translated at weighted average exchange rates for the period. The exchange differences arising on translation for consolidation are recognized in Other Comprehensive Income.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents includes cash in hand, deposits held at call with banks and other short-term highly liquid investments with original maturities of three months or less.
Deferred taxation	Deferred taxation Deferred tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realized or the deferred liability is settled. Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will be available against which the temporary differences can be utilized.
Research and development costs	Research and development costs Capitalization of expenditure on product development commences from the point at which technical feasibility and commercial viability of the product can be demonstrated and the Company is satisfied that it is probable that future economic benefits will result from the product once completed. No such costs have been capitalized to date, given the early stage of the Company's product candidate development. Expenditure on research and development activities that do not meet the above criteria is charged to the Consolidated Statement of Comprehensive Income as incurred.
Property, plant and equipment	Property, plant and equipment Property, plant and equipment are stated at cost, net of depreciation and any provision for impairment. Cost includes the original purchase price of the asset and the costs attributable to bringing the asset to its working condition for its intended use. Depreciation is calculated so as to write off the cost less their estimated residual values, on a straight-line basis over the expected useful economic lives of the assets concerned.
Intangible assets and goodwill	Intangible assets and goodwill (a) Goodwill Goodwill arises on the acquisition of subsidiaries and represents the excess of the consideration transferred over the fair value of the identifiable net assets acquired. (b) Patents Patent costs associated with the preparation, filing, and obtaining of patents are capitalized and amortized on a straight-line basis over the estimated useful lives of the patents of ten years . (c) Computer software Amortization is calculated so as to write off the cost less estimated residual values, on a straight-line basis over the expected useful economic life of two years. (d) In-process research & development ("IP R&D") IP R&D assets acquired through business combinations which, at the time of acquisition, have not reached technical feasibility are recognized at fair value. The amounts are capitalized and are not amortized but are subject to impairment testing until completion, abandonment of the projects or when the research findings are commercialized through a revenue generating project. The Company determines whether intangible assets (including goodwill) are impaired on an annual basis or where there is an impairment indicator and this requires the estimation of the higher of fair value less costs of disposal and value in use. Upon successful completion or commercialization of the relevant project, IP R&D will be reclassified to developed technology. The Company will make a determination as to the then useful life of the developed technology, generally determined by the period in which the substantial majority of the cash flows are expected to be generated, and begin amortization. In case of abandonment the asset will be impaired.
Impairment of intangible assets, goodwill and non-financial asset	Impairment of intangible assets, goodwill and non-financial assets Goodwill and intangible assets that have an indefinite useful life and intangible assets not ready to use are not subject to amortization. These assets are tested annually for impairment or more frequently if impairment indicators exist. Non-financial assets that are subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value (less costs of disposal) and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows, which are largely independent of the cash flows from other assets or group of assets (cash generating units "CGUs"). Goodwill is allocated to CGUs for the purpose of impairment testing. The allocation is made to those CGUs or groups of CGUs that are expected to benefit from the business combination in which the goodwill arose. The units or group of units are identified at the lowest level at which goodwill is monitored for internal management purposes, being the operating segments. The Company is a single cash generating unit. Goodwill that arose on the acquisition of Rhinopharma has been thus allocated to this single CGU. IP R&D is tested for impairment at this level as well, since it is the lowest level at which independent cash flows can be identified. Non-financial assets, other than goodwill, that have been previously impaired are reviewed for possible reversal of the impairment at each subsequent reporting date.
Employee Benefits	Employee Benefits (a) Pension The Company operates a defined contribution pension scheme for UK employees. Contributions payable for the year are charged to the Consolidated Statement of Comprehensive Income. The contributions are recognized as employee benefit expense when they are due. Differences between contributions payable in the year and contributions actually paid are shown as either accruals or prepayments in the Consolidated Statement of Financial Position. The Company has no further payment obligation once the contributions have been paid. (b) Bonus plans The Company recognizes a liability and an expense for bonus plans if contractually obligated or if there is a past practice that has created a constructive obligation.
Share-based payments	Share-based payments The Company operates a number of equity-settled, share-based compensation schemes. The fair value of share-based payments under such schemes is expensed on a straight-line basis over the vesting period, based on the Company's estimate of shares that will eventually vest. Where equity settled transactions are entered into with third party service providers, fair value is determined by reference to the value of the services provided in lieu of payment. The expense is measured based on the services received at the date of receipt of those services and is charged to the Consolidated Statement of Comprehensive Income over the period for which the services are received and a corresponding credit is made to reserves. For other equity-settled transactions fair value is determined using the Black-Scholes model and requires several assumptions and estimates as disclosed in note 16.
Provisions	Provisions Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation, and the amount can be reliably estimated. Provisions are measured at the present value of the expenditures expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation.
Assumed contingent obligation related to the business combinations	Assumed contingent obligation related to the business combinations On September 19, 2006, the Company acquired Rhinopharma for a total consideration of £1.52 million payable in ordinary shares. In addition, the Company assumed certain contingent obligations owed by Rhinopharma to Vernalis Pharmaceuticals Limited (“Vernalis”), which was subsequently acquired by Ligand Pharmaceuticals, Inc. (“Ligand”), under an assignment and license agreement (the "assumed contingent consideration") following the sale of IP by Vernalis to Rhinopharma. In October 2018, Vernalis was acquired by, and became a wholly owned subsidiary of, Ligand Pharmaceuticals, Inc., or Ligand). The Company refers to the assignment and license agreement as the Ligand Agreement and now refers to Vernalis as Ligand. Pursuant to the agreement Ligand (i) assigned to the Company all of its rights to certain patents and patent applications relating to ensifentrine and related compounds (the "Ligand Patents") and (ii) granted to the Company an exclusive, worldwide, royalty-bearing license under certain Ligand know-how to develop, manufacture and commercialize products (the "Licensed Products") developed using Ligand Patents, Ligand know-how and the physical stock of certain compounds. The assumed contingent obligation comprises (a) a milestone payment on obtaining the first approval of any regulatory authority for the commercialization of a Licensed Product; (b) low to mid-single digit royalties based on the future sales performance of all Licensed Products; and (c) a portion equal to a mid-twenty percent of any consideration received from any sub-licensees for the Ligand Patents and for Ligand know-how. On the date of acquisition the fair value of the assumed contingent obligation was estimated as the expected value of the milestone payment, royalty payments and sub-license payments, based on an assessment of the probability of success using standard market probabilities for respiratory drug development. The risk-weighted value of the assumed contingent arrangement was then discounted back to its net present value applying an effective interest rate of 12% . The initial fair value of the assumed contingent obligation as of December 31, 2006, was deemed to be insignificant at the date of the acquisition, so it was not recorded. The amount of royalties payable under the agreement is based on the future sales performance of certain products, and so the total amount payable is unlimited. The level of sales that may be achieved under the agreement is difficult to predict and subject to estimate, which is inherently uncertain. The value of this assumed contingent obligation is measured at amortized cost using the effective interest rate method, and is re-measured for changes in estimated cash flows, when the probability of success changes. The assumed contingent obligation is accounted for as a liability, and any adjustments made to the value of the liability will be recognized in the Consolidated Statement of Comprehensive Income for the period.
Government and other grants	Government and other grants The Company may receive government, regional or charitable grants to support its research efforts in defined projects where these grants provide for reimbursement of approved costs incurred as defined in the respective grants. Income in respect of such grants would include contributions towards the costs of research and development. Income would be recognized when costs under each grant are incurred in accordance with the terms and conditions of the grant and the collectability of the receivable is reasonably assured. Government, regional and charitable grants relating to costs would be deferred and recognized in the Consolidated Statement of Comprehensive Income over the period necessary to match them with the costs they are intended to compensate. When the cash in relation to recognized government, regional or charitable grants is not yet received the amount is included as a receivable on the Consolidated Statement of Financial Position. Where the grant income is directly related to the specific items of expenditure incurred, the income would be netted against such expenditure. Where the grant income is not a specific reimbursement of expenditure incurred, the Company would include such income under "Other income" in the Consolidated Statement of Comprehensive Income.
Financial instruments — initial recognition and subsequent measurement	Financial instruments — initial recognition and subsequent measurement The Company classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument. The Company evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified separately as financial assets, financial liabilities or equity instruments. A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. (a) Financial assets, initial recognition and measurement and subsequent measurement All financial assets not recorded at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs. Financial assets carried at fair value through profit or loss are initially recognized at fair value, and transaction costs are expensed in the income statement. The measurement of financial assets depends on their classification. Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less loss allowance. The Company does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income. (b) Financial liabilities, initial recognition and measurement and subsequent measurement Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss. The Company's financial liabilities include trade and other payables and derivative financial instruments. (c) Derivative financial instruments Derivatives are initially recognized at fair value on the date a derivative contract is entered into and are subsequently re-measured at fair value at the end of each reporting date. The Company holds only one type of derivative financial instrument, the warrants, as explained in Note 2.15. The full fair value of the derivative is classified as a non-current liability when the warrants are exercisable in more than 12 months and as a current liability when the warrants are exercisable in less than 12 months. Changes in fair value of a derivative financial liability when related to a financing arrangement are recognized in the Consolidated Statement of Comprehensive Income within Finance income or Finance expense. Fair value gains or losses on derivatives used for non-financing arrangements are recognized in other operating income or expense.
Warrants	Warrants Warrants issued by the Company to investors as part of a share subscription are compound financial instruments where the warrant meets the definition of a financial liability. The financial liability component is initially measured at fair value in the Consolidated Statement of Financial Position. Equity is measured at the residual between the subscription price for the entire instrument and the liability component. The financial liability component is remeasured depending on its classification. Equity is not remeasured.
Short Term Investments	Short Term Investments Short term investments include fixed term deposits held at banks with original maturities of more than three months but less than a year. They are classified as loans and receivables and are measured at amortized cost using the effective interest method.
Transaction costs	Transaction costs Qualifying transaction costs might be incurred in anticipation of an issuance of equity instruments and may cross reporting periods. The entity defers these costs on the balance sheet until the equity instrument is recognized. Deferred costs are subsequently reclassified as a deduction from equity when the equity instruments are recognized, as the costs are directly attributable to the equity transaction. If the equity instruments are not subsequently issued, the transaction costs are expensed. Any costs not directly attributable to the equity transaction are expensed. Transaction costs that relate to the issue of a compound financial instrument are allocated to the liability and equity components of the instrument in proportion to the allocation of proceeds. Where the liability component is held at fair value through profit or loss, the transaction costs are expensed to the Consolidated Statement of Comprehensive Income. For liabilities held at amortized cost, transaction costs are deducted from the liability and subsequently amortized. The amount of transaction costs accounted for as a deduction from equity in the period is disclosed separately in accordance with International Accounting Standard (“IAS”) 1.
Investments in subsidiaries	Investments in subsidiaries are shown at cost less any provision for impairment.
New standards, amendments and interpretations adopted by the Group	New standards, amendments and interpretations adopted by the Company The following amendments have been adopted by the Company for the first time for the financial year beginning on or after January 1, 2018: ▪ IFRS 9 "Financial instruments" ▪ IFRS 15 "Revenue from contracts with customers" IFRS 9 had no material impact on the accounting or measurement of any of the financial instruments the Company currently holds. IFRS 15 had no impact on the financial statements of the Company as it is not currently revenue generating.
New standards, amendments and interpretations issued but not effective for the financial year beginning January 1, 2016 and not early adopted	New standards, amendments and interpretations issued but not effective for the financial year beginning January 1, 2018 and not early adopted New standards and amendments to standards and interpretations have been issued but are not yet effective for annual periods beginning after January 1, 2018 (noted below), and have not been adopted in preparing these consolidated financial statements. IFRS 16 "Leases" (effective for annual periods beginning on or after January 1, 2019) IFRS 16 is effective for accounting periods beginning on or after January 1, 2019 and will replace IAS 17 "Leases". It eliminates the classification of leases as either operating leases or finance leases and, instead, introduces a single lessee accounting model. The Group will recognize new assets and liabilities for its operating leases of office leases (see Note 20). The nature of expenses related to those leases will now change because the Group will recognize a depreciation charge for right-of-use assets and interest expense on lease liabilities. Previously, the Group recognized operating lease expense on a straight-line basis over the term of the lease, and recognize assets and liabilities only to the extent that there was a timing difference between actual lease payments and the expense recognized. Instead, the Group will include the payments due under the lease in its lease liability. Based on the information currently available, using the modified retrospective method, the Group estimates that it will recognize additional lease liabilities of £316 thousand and assets of £325 thousand as of January 1, 2019. There will be no material impact on other lines in the financial statements.

Accounting policies (Tables)

Accounting policies (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract]
Description of property, plant and equipment useful life	The principal annual periods used for this purpose are: Computer hardware 3 years Office equipment 5 years

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about financial instruments [abstract]
Summary quantitative data about entity's exposure to risk	The summary quantitative date about the Company's exposure to currency risk is as follows. Figures are the pounds sterling values of balances in each currency: December 31, 2018 December 31, 2017 USD EUR USD EUR £'000s £'000s £'000s £'000s Cash and cash equivalents 8,470 21 16,806 301 Short term Investments 25,069 — 19,718 — Trade and other payables 4,329 532 276 403
Disclosure of effect of changes in foreign exchange rates	A reasonably possible strengthening (weakening) of the Euro, U.S. dollar, or pounds sterling against all other currencies as of December 31, 2018 and 2017 would have affected the measurement of the financial instruments denominated in a foreign currency and affected equity and profit and loss by the amounts shown below. This analysis assumes that all other variables remain constant. Profit or loss and equity Strengthening Weakening December 31, 2018 £'000s £'000s EUR (5% movement) (26 ) 26 USD (5% Movement) 1,461 (1,461 ) December 31, 2017 £'000s £'000s EUR (5% movement) 35 (35 ) USD (5% Movement) 1,840 (1,840 )
Disclosure of cash and cash equivalents and short term investments	As of December 31, 2018 , and December 31, 2017 , cash and cash equivalents and short term investments were placed at the following banks: Cash and Cash Equivalents Year ended December 31, 2018 Credit rating Year ended December 31, 2017 Credit rating £'000 £'000 Banks Royal Bank of Scotland 150 A1 16,623 A2 Lloyds Bank 15,862 Aa3 13,448 Aa3 Standard Chartered — A1 1,242 A1 Citibank 3,135 A1 — — Barclays 449 A2 — — Wells Fargo 188 Aa1 130 Aa1 Total 19,784 31,443 Short Term Investments Year ended December 31, 2018 Credit Year ended December 31, 2017 Credit £'000 £'000 Banks Royal Bank of Scotland 9,186 A1 15,316 A2 Lloyds Bank 1,567 Aa3 11,036 Aa3 Standard Chartered 15,450 A1 22,467 A1 Citibank 7,053 A1 — — Barclays 11,663 A2 — — Total 44,919 48,819
Disclosure of financial instruments by type of interest rate	he Company's exposure to interest rate risk, which is the risk that the interest received will fluctuate as a result of changes in market interest rates on classes of financial assets and financial liabilities, was as follows: December 31, 2018 December 31, 2017 Floating interest rate Fixed Interest rate Floating interest rate Fixed Interest rate £'000s £'000s £'000s £'000s Financial asset Cash deposits 15,082 4,702 25,720 5,723 Short Term Investments — 44,919 — 48,819 Total 15,082 49,621 25,720 54,542
Disclosure of maturity analysis of undiscounted cash outflows to repurchase derecognised financial assets or amounts payable to transferee in respect of transferred assets	The following table provides an analysis of the Company's financial liabilities. The carrying value of all balances is equal to their fair value. The Company's maturity analysis for the derivative financial instrument from the issue of warrants is given in note 17. LESS THAN 1 YEAR BETWEEN 1 AND 2 YEARS BETWEEN 2 AND 5 YEARS OVER 5 YEARS (1) £'000s £'000s £'000s £'000s At December 31, 2018 Trade payables 2,839 — — — Other payables 12 — — — Accruals 4,882 — — — Contingent obligation — — — 1,807 Total 7,733 — — 1,807 (1) This table includes the undiscounted amount of the assumed contingent obligation. See note 19. LESS THAN 1 YEAR BETWEEN 1 AND 2 YEARS BETWEEN 2 AND 5 YEARS OVER 5 YEARS (1) £'000s £'000s £'000s £'000s At December 31, 2017 Trade payables 1,214 — — — Other payables 74 — — — Accruals 5,866 — — — Contingent obligation — — — 1,807 Total 7,154 — — 1,807 (1) This table includes the undiscounted amount of the assumed contingent obligation. See note 19.
Disclosure of fair value measurement of assets	Level 3 Total £'000s £'000s At December 31, 2018 Derivative financial instrument 2,492 2,492 Total 2,492 2,492
Disclosure of fair value measurement of liabilities	Level 3 Total £'000s £'000s At December 31, 2018 Derivative financial instrument 2,492 2,492 Total 2,492 2,492 2018 Derivative financial instrument £'000s At January 1 1,273 Fair value adjustments - non cash 1,219 At December 31 2,492
Disclosure of significant unobservable inputs used in fair value measurement of liabilities	Movements in Level 3 items during the years ended December 31, 2018 , and 2017 are as follows: Derivative financial instrument 2018 2017 £'000s £'000s At January 1 1,273 7,923 Fair value adjustments recognized in profit and loss 1,219 (6,650 ) At December 31 2,492 1,273

Operating loss (Tables)

Operating loss (Tables)	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Description of operating loss	Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Operating Loss is stated after charging / (crediting): Research and development costs: Employee benefits (note 8) 3,360 3,435 2,037 Amortization of patents (note 12) 85 111 51 Legal, professional consulting and listing fees 161 331 — Other research and development expenses 15,688 19,840 2,434 Total research and development costs 19,294 23,717 4,522 General and administrative costs: Employee benefits (note 8) 3,240 2,857 865 Legal, professional consulting and listing fees 1,296 2,045 884 Amortization of computer software (note 12) 5 5 1 Loss on disposal of property, plant and equipment (note 13) — — 3 Depreciation of property, plant and equipment (note 13) 8 7 10 Operating lease charge — land and buildings 384 294 169 (Gain) / Loss on variations in foreign exchange rate (9 ) 36 139 Other general and administrative expenses 1,373 795 427 Total general and administrative costs 6,297 6,039 2,498 Operating loss 25,591 29,756 7,020

Directors' emoluments and sta_2

Directors' emoluments and staff costs (Tables)	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Disclosure of information about employees	Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 The average number of employees (excluding directors) of the Company during the year: Research and Development 7 7 5 General and Administrative 7 5 2 Total 14 12 7 Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Aggregate emoluments of directors: Salaries and other short-term employee benefits 830 897 951 Social security costs 94 103 118 Incremental payment for additional services 27 — 44 Other pension costs 10 17 19 Total directors' emoluments 961 1,017 1,132 Share-based payment charge 1,337 1,037 257 Directors' emoluments including share-based payment charge 2,298 2,054 1,389 Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Aggregate executive officers costs: Wages and salaries 857 864 512 Social security costs 83 81 22 Incremental payment for additional services — — — Share-based payment charge 769 1,332 235 Other pension costs 19 17 2 Total executive officers costs 1,728 2,294 771 Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Aggregate other staff costs: Wages and salaries 1,622 1,272 515 Social security costs 150 101 76 Incremental payment for additional services — — 58 Share-based payment charge 795 550 84 Other pension costs 34 21 9 Total other staff costs 2,601 1,944 742

Finance income and expense (Tab

Finance income and expense (Tables)	12 Months Ended
	Dec. 31, 2018
Analysis of income and expense [abstract]
Disclosure of finance income	Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Finance income: Interest received on cash balances 861 345 86 Foreign exchange gain on translating foreign currency denominated balances 1,922 — 687 Fair value adjustment on derivative financial instruments (note 17) — 6,650 1,068 Other Income — 23 — Total finance income 2,783 7,018 1,841
Disclosure of finance expense	Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Finance expense: Fair value adjustment on derivative financial instruments (note 17) 1,219 — — Transaction costs allocated to the issue of warrants (note 17) — — 586 Foreign exchange loss on translating foreign currency denominated balances — 2,392 — Remeasurement of assumed contingent arrangement — — 122 Unwinding of discount factor related to the assumed contingent arrangement (note 19) 106 73 86 Total finance expense 1,325 2,465 794

Taxation (Tables)

Taxation (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of income tax [Abstract]
Disclosure of major tax components	Year ended December 31, 2018 Year ended December 31, 2017 Year ended December 31, 2016 £'000s £'000s £'000s Analysis of tax credit for the year Current tax: U.K. tax credit (4,290 ) (5,006 ) (1,067 ) U.S. tax charge 30 306 129 Adjustment in respect of prior periods 28 (6 ) (16 ) Total tax credit (4,232 ) (4,706 ) (954 ) The difference between the total tax shown above and the amount calculated by applying the standard rate of tax to the loss before tax is as follows: Factors affecting the tax credit for the year Loss on ordinary activities before taxation (24,133 ) (25,203 ) (5,973 ) Multiplied by standard rate of corporation tax of 19% (2017: 19.25% and 2016: 20%) (4,585 ) (4,852 ) (1,195 ) Effects of: Non-deductible expenses 540 675 292 Fair value adjustment on derivative financial instruments 232 (1,280 ) (214 ) Research and development incentive (1,846 ) (2,116 ) (427 ) Temporary differences not recognized (3 ) (2 ) (4 ) Difference in overseas tax rates 8 136 56 Tax losses carried forward not recognized 1,394 2,739 554 Adjustment in respect of prior periods 28 (6 ) (16 ) Total tax credit (4,232 ) (4,706 ) (954 )
Disclosure of temporary difference, unused tax losses and unused tax credits	The following tables represent deferred tax balances recognized in the Consolidated Statement of Financial Position. There were no movements in either the deferred tax asset or the deferred tax liability. As at December 31, 2018 As at December 31, 2017 £'000s £'000s Deferred tax assets 250 250 Deferred tax liabilities (250 ) (250 ) Net balances — —

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about intangible assets [abstract]
Disclosure of reconciliation of changes in goodwill	As of December 31, 2018 As of December 31, 2017 £'000s £'000s Goodwill at January 1 and December 31 441 441

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about intangible assets [abstract]
Disclosure of reconciliation of changes in intangible assets and goodwill	IP R&D Computer software Patents Total £'000s £'000s £'000s £'000s Cost At January 1, 2017 1,469 6 592 2,067 Additions — 5 203 208 Disposals — — (68 ) (68 ) At December 31, 2017 1,469 11 727 2,207 Accumulated amortization At January 1, 2017 — 1 189 190 Charge for year — 5 111 116 Disposals — — (68 ) (68 ) At December 31, 2017 — 6 232 238 Net book value At December 31, 2017 1,469 5 495 1,969 IP R&D Computer software Patents Total £'000s £'000s £'000s £'000s Cost At January 1, 2018 1,469 11 727 2,207 Additions — 4 251 255 Disposals — — (6 ) (6 ) At December 31, 2018 1,469 15 972 2,456 Accumulated amortization At January 1, 2018 — 6 232 238 Charge for year — 5 85 90 Disposals — — (6 ) (6 ) At December 31, 2018 — 11 311 322 Net book value At December 31, 2018 1,469 4 661 2,134

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of detailed information about property, plant and equipment [abstract]
Disclosure of detailed information about property, plant and equipment	Computer hardware Total £'000s £'000s Cost At January 1, 2017 17 17 Additions 9 9 At December 31, 2017 26 26 Accumulated depreciation At January 1, 2017 3 3 Charge for the year 7 7 At December 31, 2017 10 10 Net book value At December 31, 2017 16 16 Computer hardware Total £'000s £'000s Cost At January 1, 2018 26 26 Additions 13 13 At December 31, 2018 39 39 Accumulated depreciation At January 1, 2018 10 10 Charge for the year 8 8 At December 31, 2018 18 18 Net book value At December 31, 2018 21 21

Prepayments and other receiva_2

Prepayments and other receivables (Tables)	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Description of prepayments and other receivables	As of December 31, 2018 As of December 31, 2017 £'000s £'000s Prepayments 1,362 1,138 Other receivables 1,101 672 Total prepayments and other receivables 2,463 1,810

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of share capital, reserves and other equity interest [Abstract]
Movements in the Company's share capital	The movements in the Company's share capital are summarized below: Date Description Number of shares Share Capital amounts in £'000s January 1, 2017 51,361,063 2,568 May 2, 2017 Issuance of shares 47,653,100 2,383 May 18, 2017 Issuance of shares 5,539,080 277 May 26, 2017 Issuance of shares 330,824 17 September 13, 2017 Exercise of options 133,333 6 As at December 31, 2017 105,017,400 5,251 August 9, 2018 Vesting of RSUs 58,112 3 September 20, 2018 Vesting of RSUs 251,125 12 As at December 31, 2018 105,326,637 5,266

Share-based payments charge (Ta

Share-based payments charge (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of share-based payment arrangements [Abstract]
Disclosure of indirect measurement of fair value of goods or services received, share options granted during period	The following assumptions were used for the Black-Scholes valuation of share options and RSUs granted in 2017 and 2018 . For the options granted under the Unapproved Scheme the table indicates the ranges used in determining the fair-market values, aligning with the various dates of the underlying grants. The volatility is calculated using historic weekly averages of the Company's share price over a period that is in line with the expected life of the options and RSUs. Issued in 2017 Unapproved Restricted Stock Units Options granted 4,656,828 1,052,236 Risk-free interest rate 0.29% - 0.62% 0.42%-0.62% Expected life of options 5.5 – 7.0 years 5.5 – 7.0 years Annualized volatility 71.3% - 73.3% 71.3% - 73.3% Dividend rate 0.00 % 0.00 % Vesting period 1 to 4 years 1 to 4 years Issued in 2018 Unapproved Restricted Stock Units Options granted 2,090,847 273,390 Risk-free interest rate 1.08% - 1.22% 1.08% - 1.22% Expected life of options 5.5 - 7 years 5.5 - 7 years Annualized volatility 69.88% -71.35% 69.88% -71.35% Dividend rate 0.00 % 0.00 % Vesting period 1 to 4 years 1 to 4 years
Disclosure of number and weighted average exercise prices of share options	Outstanding and exercisable share options by scheme as of December 31, 2018 : Plan Outstanding Exercisable Weighted average exercise price in £ for Outstanding Weighted average exercise price in £ for Exercisable Unapproved 8,538,130 3,336,232 1.49 1.57 EMI 213,984 206,652 3.06 3.09 Total 8,752,114 3,542,884 1.53 1.66 As of December 31, 2018 there were no restricted share options exercisable ( 2017 : nil ) and there is no exercise price for restricted share options. The options outstanding at December 31, 2018 had a weighted average remaining contractual life of 8 years ( 2017 : 8.6 years ). For 2017 and 2018 , the number of options granted and expired and the weighted average exercise price of options were as follows: Number of options Weighted average exercise price (£) At January 1, 2017 3,037,296 1.87 Options granted in 2017: Employees 3,150,846 1.32 Directors 1,505,982 1.32 Options exercised in the year (133,333 ) 1.10 Options expired in the year (33,333 ) 1.90 At December 31, 2017 7,527,458 1.53 Exercisable at December 31, 2017 797,333 2.04 Number of options Weighted average exercise price (£) At January 1, 2018 7,527,458 1.53 Options granted in 2018: Employees 1,222,089 1.46 Directors 868,758 1.46 Options forfeited in the year (799,524 ) 1.43 Options expired in the year (66,667 ) 1.75 At December 31, 2018 8,752,114 1.53 Exercisable at December 31, 2018 3,542,884 1.66 The Company had the following share options movements in the year ended December 31, 2018 : Year of issue Exercise At January 1, 2018 Options granted Options forfeited Options expired At December 31, 2018 Expiry date 2012 2.50 - 7.50 99,993 — — — 99,993 June 1, 2022 2013 2 99,990 — — — 99,990 April 15, 2023 2013 2.00 159,999 — — — 159,999 July 29, 2023 2014 1.75 109,998 — — — 109,998 May 15, 2024 2014 1.75 49,998 — — — 49,998 May 15, 2024 * 2014 1.10 - 1.75 66,667 — — (66,667 ) — August 6, 2018 ** 2015 1.25 41,997 — — — 41,997 January 29, 2025 * 2015 1.25 549,999 — — — 549,999 January 29, 2025 2016 2 260,000 — (20,000 ) — 240,000 February 2, 2026 2016 2.00 21,996 — — — 21,996 February 2, 2026 * 2016 1.80 809,996 — (133,332 ) — 676,664 August 3, 2026 2016 1.89 299,997 — — — 299,997 September 13, 2026 2016 2.04 300,000 — — — 300,000 September 16, 2026 2017 1.32 - 1.525 4,656,828 — (563,664 ) — 4,093,164 April 26, 2027 2018 1.46 — 2,090,847 (82,528 ) — 2,008,319 March 8, 2028 Total 7,527,458 2,090,847 (799,524 ) (66,667 ) 8,752,114 * Options granted under the EMI Scheme. * * Valued based on fair value of services received.
Disclosure of number and weighted average exercise prices of other equity instruments	The following table shows the number of RSUs issued in 2017. There were no RSUs forfeited, canceled or vested in 2017. The fair value of each unvested RSU at grant date was £1.32 . Number of At January 1, 2017 — Granted: Employees 705,841 Directors 346,395 At December 31, 2017 1,052,236 The following table shows the number of RSUs issued, exercised and forfeited in 2018. The fair value of each unvested RSU granted in 2018 was £1.46 . Number of At January 1, 2018 1,052,236 Granted: Employees 136,404 Directors 136,986 RSUs vested in the year (309,237 ) RSUs forfeited in the year (153,916 ) At December 31, 2018 862,473 The Company had the following RSU movements in the year ended December 31, 2018 : Year of issue Exercise At January 1, 2018 Units Units Units At December 31, 2018 Expiry date 2017 n/a 1,052,236 — (309,237 ) (13,012 ) 729,987 April 26, 2027 2018 n/a — 273,390 — (140,904 ) 132,486 March 8, 2028 Total 1,052,236 273,390 (309,237 ) (153,916 ) 862,473

Trade and other payables (Table

Trade and other payables (Tables)	12 Months Ended
	Dec. 31, 2018
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of trade and other payables	As of December 31, 2018 As of December 31, 2017 £'000s £'000s Trade payables 2,839 1,214 Other payables 12 74 Accruals 4,882 5,866 Total trade and other payables 7,733 7,154

Assumed contingent obligation_2

Assumed contingent obligation related to the business combination (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of other provisions, contingent liabilities and contingent assets [Abstract]
Disclosure of contingent liabilities in business combination	2018 2017 £'000s £'000s January 1, 2018 875 802 Impact of changes in foreign exchange rates 15 (23 ) Unwinding of discount factor 106 96 December 31, 2018 996 875 For the amount recognized December 31, 2018 of £121 thousand ( 2017 : £73 thousand ) the effect if underlying assumptions were to deviate up or down is presented in the following table (assuming the probability of success does not change):

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of share capital, reserves and other equity interest [Abstract]
Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period	Derivative financial instrument Derivative financial instrument 2018 2017 £'000s £'000s At January 1 1,273 7,923 Fair value adjustments recognized in profit or loss 1,219 (6,650 ) At December 31 2,492 1,273 For the amount recognized at December 31, 2018 , the effect when the following parameter deviates up or down is presented in the below table. Volatility (up / down 10% pts) £'000s Variable up 3,262 Base case, reported fair value 2,492 Variable down 1,738 The table below presents the assumptions in applying the Black-Scholes model to determine the fair value of the warrants. As of December 31, 2018 As of December 31, 2017 Shares available to be issued under warrants 12,401,262 12,401,262 Exercise price £ 1.7238 £ 1.7238 Risk-free interest rate 0.760 % 0.420 % Expected term to exercise 3.40 years 1.79 years Annualized volatility 60.72 % 47.35 % Dividend rate 0.00 % 0.00 %

General information (Details)

General information (Details) £ / shares in Units, $ / shares in Units, £ in Thousands, $ in Millions	May 02, 2017USD ($)	May 02, 2017GBP (£)	Feb. 10, 2017	Feb. 08, 2017	May 31, 2017USD ($)	May 31, 2017GBP (£)£ / sharesshares	Dec. 31, 2018USD ($)subsidiary	Dec. 31, 2018GBP (£)subsidiary£ / sharesshares	Dec. 31, 2017GBP (£)	May 31, 2017$ / sharesshares	Apr. 26, 2017£ / sharesshares	Apr. 26, 2017$ / sharesshares	Jul. 29, 2016£ / sharesshares
Disclosure of classes of share capital [line items]
Number of subsidiaries | subsidiary							2	2
Consolidation of shares			0.02	0.02			0.02	0.02
Number of units issued (in shares)								1,555,796,345					31,115,926
Shares issued price (in dollars or pounds per share) | £ / shares								£ 0.02873					£ 1.4365
Gross proceeds from the April 2017 Global Offering	$ 90.3	£ 70,000						£ 0	£ 70,032
Global Offering
Disclosure of classes of share capital [line items]
Number of units issued (in shares)											47,399,001	47,399,001
Gross proceeds from the April 2017 Global Offering					$ 89.9	£ 70,000	$ 89.9	70,000
IPO
Disclosure of classes of share capital [line items]
Number of units issued (in shares)											5,768,000	5,768,000
Shares issued price (in dollars or pounds per share) | $ / shares												$ 13.50
Gross proceeds from the April 2017 Global Offering							$ 90.3	70,300
Private Placement
Disclosure of classes of share capital [line items]
Number of units issued (in shares)											1,255,001	1,255,001
Shares issued price (in dollars or pounds per share) | £ / shares											£ 1.32
Gross proceeds from the April 2017 Global Offering | £								80,000
Shareholder Private Placement
Disclosure of classes of share capital [line items]
Number of units issued (in shares)						254,099				254,099	254,099	254,099
Shares issued price (in dollars or pounds per share) | £ / shares						£ 1.32					£ 1.32
Gross proceeds from the April 2017 Global Offering | £						£ 300		£ 300
Over-Allotment Option
Disclosure of classes of share capital [line items]
Gross proceeds from the April 2017 Global Offering | $					$ 9.9
Over-Allotment Option | ADS
Disclosure of classes of share capital [line items]
Number of units issued (in shares)						733,738				733,738
Shares issued price (in dollars or pounds per share) | $ / shares										$ 13.50
Over-Allotment Option | Ordinary shares
Disclosure of classes of share capital [line items]
Number of units issued (in shares)						5,869,904				5,869,904

Accounting policies - Going con

Accounting policies - Going concern (Details) £ in Thousands, $ in Millions	May 02, 2017USD ($)	May 02, 2017GBP (£)	Jul. 29, 2016GBP (£)	Dec. 31, 2018GBP (£)	Dec. 31, 2017GBP (£)	Dec. 31, 2016GBP (£)	Dec. 31, 2015GBP (£)
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract]
Loss for the year				£ (19,901)	£ (20,497)	£ (5,019)
Net assets				62,934	79,881	34,469	£ 5,434
Cash and cash equivalents and short term investments				64,700	80,300
Cash and cash equivalents				19,784	31,443	39,785	£ 3,524
Gross proceeds from the April 2017 Global Offering	$ 90.3	£ 70,000		0	70,032
Gross proceeds from issue of shares and warrants			£ 44,700	£ 0	£ 0	£ 44,750

Accounting policies - Descripti

Accounting policies - Description of property, plant and equipment useful life (Details)	12 Months Ended
	Dec. 31, 2018
Computer hardware
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment life	3 years
Office equipment
Disclosure of detailed information about property, plant and equipment [line items]
Property, plant and equipment life	5 years

Accounting policies - Intangibl

Accounting policies - Intangible assets and goodwill (Details)	12 Months Ended
	Dec. 31, 2018
Patents
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives	10 years
Computer software
Disclosure of detailed information about intangible assets [line items]
Estimated useful lives	2 years

Accounting policies - Assumed c

Accounting policies - Assumed contingent obligation related to the business combinations (Details) - GBP (£) £ in Thousands	Sep. 19, 2006	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about business combination [line items]
Effective interest rate			12.00%
Rhinopharma Limited
Disclosure of detailed information about business combination [line items]
Consideration payable	£ 1,520
Effective interest rate	12.00%	12.00%

Accounting policies - New stand

Accounting policies - New standards, amendments and interpretations issued but not effective (Details)	Jan. 01, 2019GBP (£)
Disclosure of changes in accounting policies, accounting estimates and errors [Abstract]
Lease liabilities	£ 316
Lease assets	£ 325

Financial Instruments - Summary

Financial Instruments - Summary quantitative data about entity's exposure to risk (Details) - Currency risk - GBP (£) £ in Thousands	Dec. 31, 2018	Dec. 31, 2017
USD | Cash and cash equivalents
Disclosure of credit risk exposure [line items]
Cash deposits	£ 8,470	£ 16,806
USD | Short Term Investments
Disclosure of credit risk exposure [line items]
Cash deposits	25,069	19,718
USD | Trade and other payables
Disclosure of credit risk exposure [line items]
Cash deposits	4,329	276
EUR | Cash and cash equivalents
Disclosure of credit risk exposure [line items]
Cash deposits	21	301
EUR | Short Term Investments
Disclosure of credit risk exposure [line items]
Cash deposits	0	0
EUR | Trade and other payables
Disclosure of credit risk exposure [line items]
Cash deposits	£ 532	£ 403

Financial Instruments - Disclos

Financial Instruments - Disclosure of effect of changes in foreign exchange rates [text block] (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
EUR | Strengthening
Disclosure of credit risk exposure [line items]
Profit or loss and equity	£ (26)	£ 35
EUR | Weakening
Disclosure of credit risk exposure [line items]
Profit or loss and equity	26	(35)
USD | Strengthening
Disclosure of credit risk exposure [line items]
Profit or loss and equity	1,461	1,840
USD | Weakening
Disclosure of credit risk exposure [line items]
Profit or loss and equity	£ (1,461)	£ (1,840)

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of fair value measurement of assets [line items]
Cash deposits	£ 19,784	£ 31,443	£ 39,785	£ 3,524
Short-term deposits, not classified as cash equivalents	£ 44,919	48,819
Increase in interest rates	0.25%
Bottom of range
Disclosure of fair value measurement of assets [line items]
Trade payable term	30 days
Rates of interest	0.00%
Top of range
Disclosure of fair value measurement of assets [line items]
Trade payable term	45 days
Rates of interest	2.87%
Derivative financial instrument
Disclosure of fair value measurement of assets [line items]
Gains (losses) recognised in profit or loss, fair value measurement, liabilities	£ (1,219)
Derivative financial instrument | Level 3
Disclosure of fair value measurement of assets [line items]
Gains (losses) recognised in profit or loss, fair value measurement, liabilities	£ 1,219	£ (6,650)

Financial Instruments - Discl_2

Financial Instruments - Disclosure Of Detailed Information About Cash And Cash Equivalents Placement Explanatory (Details) - GBP (£) £ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of financial assets [line items]
Cash and cash equivalents	£ 19,784	£ 31,443	£ 39,785	£ 3,524
Short term investments	44,919	48,819
Royal Bank of Scotland
Disclosure of financial assets [line items]
Cash and cash equivalents	150	16,623
Short term investments	9,186	15,316
Lloyds Bank
Disclosure of financial assets [line items]
Cash and cash equivalents	15,862	13,448
Short term investments	1,567	11,036
Standard Chartered
Disclosure of financial assets [line items]
Cash and cash equivalents	0	1,242
Short term investments	15,450	22,467
Citibank [Member] [Domain]
Disclosure of financial assets [line items]
Cash and cash equivalents	3,135
Short term investments	7,053
Barclays [Member] [Domain] [Domain]
Disclosure of financial assets [line items]
Cash and cash equivalents	449
Short term investments	11,663
Wells Fargo
Disclosure of financial assets [line items]
Cash and cash equivalents	£ 188	130
Short term investments		£ 0

Financial Instruments - Discl_3

Financial Instruments - Disclosure of financial instruments by type of interest rate (Details) - GBP (£) £ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of financial instruments by type of interest rate [line items]
Short-term deposits, not classified as cash equivalents	£ 44,919	£ 48,819
Interest rate risk | Floating interest rate
Disclosure of financial instruments by type of interest rate [line items]
Cash deposits	15,082	25,720
Interest rate risk | Fixed Interest rate
Disclosure of financial instruments by type of interest rate [line items]
Cash deposits	49,621	54,542
Cash deposits | Interest rate risk | Floating interest rate
Disclosure of financial instruments by type of interest rate [line items]
Cash deposits	15,082	25,720
Cash deposits | Interest rate risk | Fixed Interest rate
Disclosure of financial instruments by type of interest rate [line items]
Cash deposits	4,702	5,723
Short Term Investments | Interest rate risk | Floating interest rate
Disclosure of financial instruments by type of interest rate [line items]
Cash deposits	0	0
Short Term Investments | Interest rate risk | Fixed Interest rate
Disclosure of financial instruments by type of interest rate [line items]
Cash deposits	£ 44,919	£ 48,819

Financial Instruments - Discl_4

Financial Instruments - Disclosure of maturity analysis of undiscounted cash outflows to repurchase derecognised financial assets or amounts payable to transferee in respect of transferred assets (Details) - Liquidity risk - GBP (£)	Dec. 31, 2018	Dec. 31, 2017
LESS THAN 1 YEAR
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	£ 7,733,000	£ 7,154,000
BETWEEN 1 AND 2 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
BETWEEN 2 AND 5 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
OVER 5 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	1,807,000	1,807,000
Trade payables | LESS THAN 1 YEAR
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	2,839,000	1,214,000
Trade payables | BETWEEN 1 AND 2 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Trade payables | BETWEEN 2 AND 5 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Trade payables | OVER 5 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Other payables | LESS THAN 1 YEAR
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	12,000	74,000
Other payables | BETWEEN 1 AND 2 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Other payables | BETWEEN 2 AND 5 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Other payables | OVER 5 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Accruals | LESS THAN 1 YEAR
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	4,882,000	5,866,000
Accruals | BETWEEN 1 AND 2 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Accruals | BETWEEN 2 AND 5 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Accruals | OVER 5 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Contingent obligation | LESS THAN 1 YEAR
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Contingent obligation | BETWEEN 1 AND 2 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Contingent obligation | BETWEEN 2 AND 5 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	0	0
Contingent obligation | OVER 5 YEARS
Disclosure of financial liabilities [line items]
Trade and other payables, undiscounted cash flows	£ 1,807,000	£ 1,807,000

Financial Instruments - Discl_5

Financial Instruments - Disclosure of fair value measurement of assets and liabilities (Details) - Derivative financial instrument - GBP (£) £ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of fair value measurement of assets [line items]
Financial assets	£ 2,492	£ 1,273
Level 3
Disclosure of fair value measurement of assets [line items]
Financial assets	£ 2,492	£ 1,273	£ 7,923

Financial Instruments - Discl_6

Financial Instruments - Disclosure of significant unobservable inputs used in fair value measurement of assets and liabilities (Details) - GBP (£) £ in Thousands	Jul. 29, 2016	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of changes in fair value measurement, liabilities [abstract]
Initial recognition of derivative financial instrument	£ 9,000
Derivative financial instrument
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance		£ 1,273
Fair value adjustments recognized in profit and loss		(1,219)
Ending balance		2,492	£ 1,273
Level 3 | Derivative financial instrument
Reconciliation of changes in fair value measurement, liabilities [abstract]
Beginning balance		1,273	7,923
Fair value adjustments recognized in profit and loss		1,219	(6,650)
Ending balance		£ 2,492	£ 1,273

Financial Instruments - Change

Financial Instruments - Change in liabilities arising from financing activities (Details) - Derivative financial instrument £ in Thousands	12 Months Ended
	Dec. 31, 2018GBP (£)
Changes in fair value measurement, liabilities [abstract]
Beginning balance	£ 1,273
Fair value adjustments - non cash	1,219
Ending balance	£ 2,492

Critical accounting estimates_2

Critical accounting estimates and judgments (Details) £ / shares in Units, £ in Thousands	Sep. 19, 2006	Dec. 31, 2018GBP (£)£ / sharesshares	Dec. 31, 2017GBP (£)shares	Dec. 31, 2016GBP (£)	Jul. 31, 2016shareswarrant	Jul. 29, 2016shareswarrant£ / shares
Disclosure of detailed information about business combination [line items]
Assumed contingent obligation		£ 996	£ 875	£ 802
Discount percent			12.00%
Number of units issued (in shares) | shares		1,555,796,345				31,115,926
Placing price (in pounds per unit) | £ / shares		£ 0.02873				£ 1.4365
Number of ordinary shares (in shares) | shares					1	1
Number warrants (in warrants) | warrant					1	1
Number of shares subscribed from warrant maximum (in shares) | shares		622,318,538
Research and development expense		£ 19,294	£ 23,717	£ 4,522
Rhinopharma Limited
Disclosure of detailed information about business combination [line items]
Reported change to the value of the liability		£ 121	£ 100
Discount percent	12.00%	12.00%
Warrants
Disclosure of detailed information about business combination [line items]
Number of shares subscribed from warrant maximum (in shares) | shares		12,401,262	12,401,262			12,401,262
Clinical Research Organization
Disclosure of detailed information about business combination [line items]
Research and development expense		£ 14,000
Accruals		3,400
Prepayments		£ 700

Earnings per share (Details)

Earnings per share (Details) - £ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of earnings per share [Abstract]
Basic loss per share (pounds per share)	£ 0.189	£ 0.234	£ 0.150
Weighted average number of ordinary shares (in shares)	105,110,504	87,748,031	33,499,413

Segmental reporting (Details)

Segmental reporting (Details)	12 Months Ended
	Dec. 31, 2018segment
Disclosure of entity's operating segments [Abstract]
Number of operating and reportable segments	1

Operating loss - Description Of

Operating loss - Description Of Operating Loss (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Research and development costs:
Total research and development costs	£ 19,294	£ 23,717	£ 4,522
General and administrative costs:
Total general and administrative costs	6,297	6,039	2,498
Operating loss	25,591	29,756	7,020
Research and development costs
Research and development costs:
Employee benefits (note 8)	3,360	3,435	2,037
Legal, professional consulting and listing fees	161	331	0
Other research and development expenses	15,688	19,840	2,434
Total research and development costs	19,294	23,717	4,522
General and administrative costs:
Employee benefits (note 8)	3,360	3,435	2,037
Legal, professional consulting and listing fees	161	331	0
Research and development costs | Patents
Research and development costs:
Amortization	85	111	51
General and administrative costs:
Amortization	85	111	51
General and administrative costs
Research and development costs:
Employee benefits (note 8)	3,240	2,857	865
Legal, professional consulting and listing fees	1,296	2,045	884
General and administrative costs:
Employee benefits (note 8)	3,240	2,857	865
Legal, professional consulting and listing fees	1,296	2,045	884
Loss on disposal of property, plant and equipment (note 13)	0	0	3
Depreciation of property, plant and equipment (note 13)	8	7	10
Operating lease charge — land and buildings	384	294	169
(Gain) / Loss on variations in foreign exchange rate	(9)	36	139
Other general and administrative expenses	1,373	795	427
Total general and administrative costs	6,297	6,039	2,498
Operating loss	25,591	29,756	7,020
General and administrative costs | Computer software
Research and development costs:
Amortization	5	5	1
General and administrative costs:
Amortization	£ 5	£ 5	£ 1

Directors' emoluments and sta_3

Directors' emoluments and staff costs (Details)	12 Months Ended
	Dec. 31, 2018GBP (£)employee	Dec. 31, 2017GBP (£)employee	Dec. 31, 2016GBP (£)employee
Disclosure of transactions between related parties [line items]
The average number of employees (excluding directors) of the Company during the year: | employee	14	12	7
Aggregate emoluments of directors:
Share-based payment charge	£ 2,900,000	£ 2,920,000
Aggregate other staff costs:
Share-based payment charge	2,900,000	2,920,000
Post-employment benefit expense, defined contribution plans	63,000	55,000	£ 30,000
Prepaid or accrued contributions	0	0	0
Directors
Aggregate emoluments of directors:
Salaries and other short-term employee benefits	830,000	897,000	951,000
Social security costs	94,000	103,000	118,000
Incremental payment for additional services	27,000	0	44,000
Other pension costs	10,000	17,000	19,000
Total directors' emoluments	961,000	1,017,000	1,132,000
Share-based payment charge	1,337,000	1,037,000	257,000
Directors' emoluments including share-based payment charge	2,298,000	2,054,000	1,389,000
Aggregate other staff costs:
Social security costs	94,000	103,000	118,000
Incremental payment for additional services	27,000	0	44,000
Share-based payment charge	1,337,000	1,037,000	257,000
Other pension costs	10,000	17,000	19,000
Executive Officers
Aggregate emoluments of directors:
Social security costs	83,000	81,000	22,000
Incremental payment for additional services	0	0	0
Other pension costs	19,000	17,000	2,000
Share-based payment charge	769,000	1,332,000	235,000
Aggregate other staff costs:
Wages and salaries	857,000	864,000	512,000
Social security costs	83,000	81,000	22,000
Incremental payment for additional services	0	0	0
Share-based payment charge	769,000	1,332,000	235,000
Other pension costs	19,000	17,000	2,000
Total other staff costs	1,728,000	2,294,000	771,000
Other Staff
Aggregate emoluments of directors:
Social security costs	150,000	101,000	76,000
Incremental payment for additional services	0	0	58,000
Other pension costs	34,000	21,000	9,000
Share-based payment charge	795,000	550,000	84,000
Aggregate other staff costs:
Wages and salaries	1,622,000	1,272,000	515,000
Social security costs	150,000	101,000	76,000
Incremental payment for additional services	0	0	58,000
Share-based payment charge	795,000	550,000	84,000
Other pension costs	34,000	21,000	9,000
Total other staff costs	£ 2,601,000	£ 1,944,000	£ 742,000
Research and Development
Disclosure of transactions between related parties [line items]
The average number of employees (excluding directors) of the Company during the year: | employee	7	7	5
General and Administrative
Disclosure of transactions between related parties [line items]
The average number of employees (excluding directors) of the Company during the year: | employee	7	5	2

Finance income and expense (Det

Finance income and expense (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Finance income:
Interest received on cash balances	£ 861	£ 345	£ 86
Foreign exchange gain on translating foreign currency denominated balances	1,922	0	687
Fair value adjustment on derivative financial instruments (note 17)	0	6,650	1,068
Other Income	0	23	0
Total finance income	2,783	7,018	1,841
Finance expense:
Fair value adjustment on derivative financial instruments (note 17)	1,219	0	0
Transaction costs allocated to the issue of warrants (note 17)		0	586
Foreign exchange loss on translating foreign currency denominated balances	0	2,392	0
Remeasurement of assumed contingent arrangement	0	0	122
Unwinding of discount factor related to the assumed contingent arrangement (note 19)	106	73	86
Total finance expense	£ 1,325	£ 2,465	£ 794

Taxation - Disclosure of major

Taxation - Disclosure of major components of tax expense (income) (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current tax:
Adjustment in respect of prior periods	£ 28	£ (6)	£ (16)
Total tax credit	(4,232)	(4,706)	(954)
Factors affecting the tax credit for the year
Loss on ordinary activities before taxation	(24,133)	(25,203)	(5,973)
Multiplied by standard rate of corporation tax of 19% (2017: 19.25% and 2016: 20%)	£ (4,585)	£ (4,852)	£ (1,195)
Standard rate of corporation tax	19.00%	19.25%	20.00%
Effects of:
Non-deductible expenses	£ 540	£ 675	£ 292
Fair value adjustment on derivative financial instruments	232	(1,280)	(214)
Research and development incentive	(1,846)	(2,116)	(427)
Temporary differences not recognized	(3)	(2)	(4)
Difference in overseas tax rates	8	136	56
Tax losses carried forward not recognized	1,394	2,739	554
Adjustment in respect of prior periods	28	(6)	(16)
Total tax credit	(4,232)	(4,706)	(954)
UK
Current tax:
U.K. tax credit	(4,290)	(5,006)	(1,067)
US
Current tax:
U.K. tax credit	£ 30	£ 306	£ 129
Factors affecting the tax credit for the year
Standard rate of corporation tax	27.60%	35.00%	35.00%

Taxation - Narrative (Details)

Taxation - Narrative (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Standard rate of corporation tax	19.00%	19.25%	20.00%
Unrecognized deferred tax asset percent	17.00%	17.00%
Unrecognized deferred tax asset	£ 6,650	£ 5,430
U.S. federal tax
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Standard rate of corporation tax	27.60%	35.00%	35.00%

Taxation - Disclosure of tempor

Taxation - Disclosure of temporary difference, unused tax losses and unused tax credits (Details) - GBP (£) £ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Disclosure of income tax [Abstract]
Deferred tax assets	£ 250	£ 250
Deferred tax liabilities	(250)	(250)
Net balances	£ 0	£ 0

Goodwill (Details)

Goodwill (Details) - GBP (£)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of detailed information about intangible assets [abstract]
Goodwill at January 1 and December 31	£ 441,000	£ 441,000
Market capitalization	92,200,000	109,700,000
Equity attributable to owners of parent	62,934,000	£ 79,881,000	£ 34,469,000	£ 5,434,000
Impairment loss recognised in profit or loss, intangible assets other than goodwill	£ 0

Intangible assets - Disclosure

Intangible assets - Disclosure of reconciliation of changes in intangible assets and goodwill (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of detailed information about intangible assets [line items]
Beginning balance	£ 1,969
Ending balance	2,134	£ 1,969
Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	2,207	2,067
Additions	255	208
Disposals	(6)	(68)
Ending balance	2,456	2,207
Accumulated depreciation
Disclosure of detailed information about intangible assets [line items]
Beginning balance	238	190
Disposals	(6)	(68)
Charge for year	90	116
Ending balance	322	238
IP R&D
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,469
Ending balance	1,469	1,469
IP R&D | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	1,469	1,469
Additions	0	0
Disposals	0	0
Ending balance	1,469	1,469
Computer software
Disclosure of detailed information about intangible assets [line items]
Beginning balance	5
Ending balance	4	5
Computer software | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	11	6
Additions	4	5
Disposals	0	0
Ending balance	15	11
Computer software | Accumulated depreciation
Disclosure of detailed information about intangible assets [line items]
Beginning balance	6	1
Disposals	0	0
Charge for year	5	5
Ending balance	11	6
Patents
Disclosure of detailed information about intangible assets [line items]
Beginning balance	495
Ending balance	661	495
Patents | Cost
Disclosure of detailed information about intangible assets [line items]
Beginning balance	727	592
Additions	251	203
Disposals	(6)	(68)
Ending balance	972	727
Patents | Accumulated depreciation
Disclosure of detailed information about intangible assets [line items]
Beginning balance	232	189
Disposals	(6)	(68)
Charge for year	85	111
Ending balance	£ 311	£ 232

Intangible assets - Narrative (

Intangible assets - Narrative (Details) - GBP (£)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of detailed information about intangible assets [line items]
Market capitalization	£ 92,200,000	£ 109,700,000
Net assets	62,934,000	£ 79,881,000	£ 34,469,000	£ 5,434,000
Impairment	£ 0
Patents
Disclosure of detailed information about intangible assets [line items]
Amortization period	10 years

Property, plant and equipment_2

Property, plant and equipment (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cost
Property, plant and equipment beginning balance	£ 16
Property, plant and equipment ending balance	21	£ 16
Accumulated depreciation
Property, plant and equipment beginning balance	16
Property, plant and equipment ending balance	21	16
Net book value
Property plant and equipment	16	16
Cost
Cost
Property, plant and equipment beginning balance	26	17
Additions	13	9
Property, plant and equipment ending balance	39	26
Accumulated depreciation
Property, plant and equipment beginning balance	26	17
Property, plant and equipment ending balance	39	26
Net book value
Property plant and equipment	26	17
Accumulated depreciation
Cost
Property, plant and equipment beginning balance	10	3
Property, plant and equipment ending balance	18	10
Accumulated depreciation
Property, plant and equipment beginning balance	10	3
Charge for the year	8	7
Property, plant and equipment ending balance	18	10
Net book value
Property plant and equipment	10	3
Computer hardware
Cost
Property, plant and equipment beginning balance	16
Property, plant and equipment ending balance	21	16
Accumulated depreciation
Property, plant and equipment beginning balance	16
Property, plant and equipment ending balance	21	16
Net book value
Property plant and equipment	16	16
Computer hardware | Cost
Cost
Property, plant and equipment beginning balance	26	17
Additions	13	9
Property, plant and equipment ending balance	39	26
Accumulated depreciation
Property, plant and equipment beginning balance	26	17
Property, plant and equipment ending balance	39	26
Net book value
Property plant and equipment	26	17
Computer hardware | Accumulated depreciation
Cost
Property, plant and equipment beginning balance	10	3
Property, plant and equipment ending balance	18	10
Accumulated depreciation
Property, plant and equipment beginning balance	10	3
Charge for the year	8	7
Property, plant and equipment ending balance	18	10
Net book value
Property plant and equipment	£ 10	£ 3

Prepayments and other receiva_3

Prepayments and other receivables (Details) - GBP (£) £ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Subclassifications of assets, liabilities and equities [abstract]
Prepayments	£ 1,362	£ 1,138
Other receivables	1,101	672
Total prepayments and other receivables	£ 2,463	£ 1,810

Share Capital - Movements in th

Share Capital - Movements in the Company's share capital (Details) £ in Thousands	Sep. 20, 2018GBP (£)shares	Aug. 09, 2018GBP (£)shares	Sep. 13, 2017GBP (£)shares	May 26, 2017GBP (£)shares	May 18, 2017GBP (£)shares	May 02, 2017GBP (£)shares	Dec. 31, 2018GBP (£)shares	Dec. 31, 2017GBP (£)shares	Dec. 31, 2016GBP (£)shares
Number of shares
Beginning balance (in shares) | shares							105,017,400	51,361,063
Issuance of shares (in shares) | shares				330,824	5,539,080	47,653,100	2,090,847
Exercise of options (in shares) | shares	251,125	58,112	133,333					133,333
Ending balance (in shares) | shares							105,326,637	105,017,400	51,361,063
Share Capital amounts in £'000s
Beginning balance							£ 5,251	£ 2,568
Issuance of shares				£ 17	£ 277	£ 2,383	15	70,325	£ 35,707
Exercise of options			£ 6
Vesting of RSUs	£ 12	£ 3
Ending balance							£ 5,266	£ 5,251	£ 2,568

Share Capital - Narrative (Deta

Share Capital - Narrative (Details) £ / shares in Units, $ / shares in Units, $ in Millions	Sep. 20, 2018shares	Aug. 09, 2018shares	Sep. 13, 2017GBP (£)shares£ / shares	May 02, 2017USD ($)	May 02, 2017GBP (£)	Apr. 26, 2017GBP (£)£ / sharesshares	Feb. 10, 2017	Feb. 08, 2017£ / shares	Jul. 29, 2016GBP (£)shareswarrant£ / shares	May 31, 2017USD ($)	May 31, 2017GBP (£)£ / sharesshares	Dec. 31, 2018USD ($)shares	Dec. 31, 2018GBP (£)shares£ / shares	Dec. 31, 2017GBP (£)shares	Dec. 31, 2016GBP (£)shares	May 31, 2017$ / sharesshares	Apr. 26, 2017$ / sharesshares	Feb. 07, 2017£ / shares	Jul. 31, 2016shareswarrant
Disclosure of classes of share capital [line items]
Consolidation of shares							0.02	0.02				0.02	0.02
Price per share (in pounds per share) | £ / shares								£ 0.05					£ 0.05					£ 0.001
Number of shares authorized													200,000,000
Share capital | £													£ 10,000,000
Number of shares allotted, unrestricted, called up and fully paid (in shares)													105,326,637	105,017,400	51,361,063
Number of ordinary shares in issue (in shares)									31,115,926				1,555,796,345
Shares issued price (in dollars or pounds per share) | £ / shares									£ 1.4365				£ 0.02873
Gross proceeds from the April 2017 Global Offering				$ 90.3	£ 70,000,000								£ 0	£ 70,032,000
Finance expense from movements in exchange rates | £						£ 439,000
Saving on commission payable | £						31,000
Finance expense | £						£ 408,000			£ 2,900,000					£ 7,453,000	£ 2,325,000
Number of shares subscribed from warrant maximum (in shares)	251,125	58,112	133,333											133,333
Exercise price (pounds per share) | £ / shares			£ 1.10
Proceeds from warrant exercise | £			£ 147,000
Number of ordinary shares (in shares)									1										1
Number warrants (in warrants) | warrant									1										1
Number of shares subscribed (in shares)									0.4
Exercise price percent									120.00%
Gross proceeds from issue of shares and warrants | £									£ 44,700,000				0	£ 0	£ 44,750,000
Ordinary shares
Disclosure of classes of share capital [line items]
Finance expense | £									£ 2,300,000
Global Offering
Disclosure of classes of share capital [line items]
Number of ordinary shares in issue (in shares)						47,399,001											47,399,001
Gross proceeds from the April 2017 Global Offering										$ 89.9	£ 70,000,000	$ 89.9	70,000,000
IPO
Disclosure of classes of share capital [line items]
Number of ordinary shares in issue (in shares)						5,768,000											5,768,000
Shares issued price (in dollars or pounds per share) | $ / shares																	$ 13.50
Gross proceeds from the April 2017 Global Offering												$ 90.3	70,300,000
Private Placement
Disclosure of classes of share capital [line items]
Number of ordinary shares in issue (in shares)						1,255,001											1,255,001
Shares issued price (in dollars or pounds per share) | £ / shares						£ 1.32
Gross proceeds from the April 2017 Global Offering | £													80,000,000
Over-Allotment Option
Disclosure of classes of share capital [line items]
Gross proceeds from the April 2017 Global Offering | $										$ 9.9
Over-Allotment Option | ADS
Disclosure of classes of share capital [line items]
Number of ordinary shares in issue (in shares)											733,738					733,738
Shares issued price (in dollars or pounds per share) | $ / shares																$ 13.50
Over-Allotment Option | Ordinary shares
Disclosure of classes of share capital [line items]
Number of ordinary shares in issue (in shares)											5,869,904					5,869,904
Shareholder Private Placement
Disclosure of classes of share capital [line items]
Number of ordinary shares in issue (in shares)						254,099					254,099					254,099	254,099
Shares issued price (in dollars or pounds per share) | £ / shares						£ 1.32					£ 1.32
Gross proceeds from the April 2017 Global Offering | £											£ 300,000		£ 300,000
Restricted Stock Units
Disclosure of classes of share capital [line items]
Number of shares subscribed from warrant maximum (in shares)												309,237	309,237

Share-based payments charge - N

Share-based payments charge - Narrative (Details)	May 26, 2017shares	May 18, 2017shares	May 02, 2017shares	Dec. 31, 2018GBP (£)sharesyearhour	Dec. 31, 2017GBP (£)sharesyear	Dec. 31, 2018sharesyearvesting_method
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based payment charge | £				£ 2,900,000	£ 2,920,000
Number of share options granted (in shares)	330,824	5,539,080	47,653,100	2,090,847
Weighted average remaining contractual life of outstanding share options | year				8	8.6	8
Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of vesting methods | vesting_method						2
Exercise period						10 years
Number of share options granted (in shares)				2,090,847	4,656,828
EMI
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise period				10 years
Hours worked per week (at least) | hour				25
Percent of working time (at least)				75.00%
Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted (in shares)				273,390	1,052,236
Number of other equity instruments exercisable in share-based payment arrangement (in shares)				0	0	0
Granted, Weighted average exercise price in £ for Outstanding (pounds per share) | £				£ 1.46	£ 1.32
Bottom of range | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				1 year	1 year	3 years
Bottom of range | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				1 year	1 year
Top of range | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				4 years	4 years	4 years
Top of range | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				4 years	4 years
Method one, tranche one | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period						1 year
Vesting portion				0.3333
Method one, tranche one | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting portion				0.3333
Method one, tranche two | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period						2 years
Vesting portion				0.3333
Method one, tranche two | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting portion				0.3333
Method one, tranche three | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period						3 years
Vesting portion				0.3333
Method one, tranche three | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting portion				0.3333
Method two, tranche one | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting portion				0.25
Method two, tranche one | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting portion				0.25
Method two, tranche two | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting portion				0.25
Method two, tranche two | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting portion				0.25
Method two, tranche three | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting portion				0.25
Method two, tranche three | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting portion				0.25
Method two, tranche four | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period						4 years
Vesting portion				0.25
Method two, tranche four | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting portion				0.25
Advisor Options | Bottom of range | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise period				1 year
Advisor Options | Top of range | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise period				2 years
Incentive Award Plan 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Fair value of equity instruments | £				£ 2,320,000	£ 5,330,000
Incentive Award Plan 2017 | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted (in shares)				2,090,847	1,052,236
Incentive Award Plan 2017 | EMI
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted (in shares)					4,656,828
Incentive Award Plan 2017 | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of share options granted (in shares)				273,390
Incentive Award Plan 2017 | Bottom of range | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				3 years
Incentive Award Plan 2017 | Top of range | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				4 years
Incentive Award Plan 2017 | Method one, tranche one | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				1 year
Incentive Award Plan 2017 | Method one, tranche two | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				2 years
Incentive Award Plan 2017 | Method one, tranche three | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				3 years
Incentive Award Plan 2017 | Method two, tranche two | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				2 years
Incentive Award Plan 2017 | Method two, tranche three | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				3 years
Incentive Award Plan 2017 | Method two, tranche four | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting period				4 years

Share-based payments charge - D

Share-based payments charge - Disclosure of indirect measurement of fair value of goods or services received, share options granted during period (Details)	May 26, 2017shares	May 18, 2017shares	May 02, 2017shares	Dec. 31, 2018sharesyear	Dec. 31, 2017sharesyear	Dec. 31, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted (in shares) | shares	330,824	5,539,080	47,653,100	2,090,847
Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted (in shares) | shares				273,390	1,052,236
Dividend rate				0.00%	0.00%
Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted (in shares) | shares				2,090,847	4,656,828
Dividend rate				0.00%	0.00%
Bottom of range | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate				1.08%	0.29%
Expected life of options				5.5	5.5
Annualized volatility				69.88%	71.30%
Vesting period				1 year	1 year
Bottom of range | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate				1.08%	0.42%
Expected life of options				5.5	5.5
Annualized volatility				69.88%	71.30%
Vesting period				1 year	1 year	3 years
Top of range | Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate				1.22%	0.62%
Expected life of options				7	7
Annualized volatility				71.35%	73.30%
Vesting period				4 years	4 years
Top of range | Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate				1.22%	0.62%
Expected life of options				7	7
Annualized volatility				71.35%	73.30%
Vesting period				4 years	4 years	4 years

Share-based payments charge - S

Share-based payments charge - Share options movements (Details)	Sep. 20, 2018shares	Aug. 09, 2018shares	Sep. 13, 2017shares	May 26, 2017shares	May 18, 2017shares	May 02, 2017shares	Dec. 31, 2018GBP (£)shares	Dec. 31, 2017shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Beginning balance (in shares)							7,527,458	3,037,296
Options granted (in shares)				330,824	5,539,080	47,653,100	2,090,847
Options exercised (in shares)	(251,125)	(58,112)	(133,333)					(133,333)
Options forfeited (in shares)							(799,524)
Options expired (in shares)							(66,667)	(33,333)
Ending balance (in shares)							8,752,114	7,527,458
Year Of Issue, 2012, Expiry Date June 1, 2022
Disclosure of terms and conditions of share-based payment arrangement [line items]
Beginning balance (in shares)							99,993
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							0
Ending balance (in shares)							99,993	99,993
Year Of Issue, 2012, Expiry Date June 1, 2022 | Bottom of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 2.50
Year Of Issue, 2012, Expiry Date June 1, 2022 | Top of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							7.50
Year Of Issue, 2013, Expiry Date April 15, 2023
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 2
Beginning balance (in shares)							99,990
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							0
Ending balance (in shares)							99,990	99,990
Year Of Issue, 2013, Expiry Date July 29, 2023
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 2
Beginning balance (in shares)							159,999
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							0
Ending balance (in shares)							159,999	159,999
Year Of Issue, 2014, Expiry Date May 15, 2024
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 1.75
Beginning balance (in shares)							109,998
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							0
Ending balance (in shares)							109,998	109,998
Year Of Issue, 2014, Expiry Date August 6, 2018
Disclosure of terms and conditions of share-based payment arrangement [line items]
Beginning balance (in shares)							66,667
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							(66,667)
Ending balance (in shares)							0	66,667
Year Of Issue, 2014, Expiry Date August 6, 2018 | Bottom of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 1.10
Year Of Issue, 2014, Expiry Date August 6, 2018 | Top of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							1.75
Year Of Issue, 2015, Expiry Date January 29, 2025
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 1.25
Beginning balance (in shares)							549,999
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							0
Ending balance (in shares)							549,999	549,999
Year Of Issue, 2016, Expiry Date February 2, 2026
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 2
Beginning balance (in shares)							260,000
Options granted (in shares)							0
Options forfeited (in shares)							(20,000)
Options expired (in shares)							0
Ending balance (in shares)							240,000	260,000
Year Of Issue, 2016, Expiry Date August 3, 2026
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 1.80
Beginning balance (in shares)							809,996
Options granted (in shares)							0
Options forfeited (in shares)							(133,332)
Options expired (in shares)							0
Ending balance (in shares)							676,664	809,996
Year Of Issue, 2016, Expiry Date September 13, 2026
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 1.89
Beginning balance (in shares)							299,997
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							0
Ending balance (in shares)							299,997	299,997
Year Of Issue, 2016, Expiry Date September 16, 2026
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 2.04
Beginning balance (in shares)							300,000
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							0
Ending balance (in shares)							300,000	300,000
Year Of Issue, 2017, Expiry Date April 26, 2027
Disclosure of terms and conditions of share-based payment arrangement [line items]
Beginning balance (in shares)							4,656,828
Options granted (in shares)							0
Options forfeited (in shares)							(563,664)
Options expired (in shares)							0
Ending balance (in shares)							4,093,164	4,656,828
Year Of Issue, 2017, Expiry Date April 26, 2027 | Bottom of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 1.32
Year Of Issue, 2017, Expiry Date April 26, 2027 | Top of range
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							1.525
Year Of Issue, 2018, Expiry Date March 9, 2028
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 1.46
Beginning balance (in shares)							0
Options granted (in shares)							2,090,847
Options forfeited (in shares)							(82,528)
Options expired (in shares)							0
Ending balance (in shares)							2,008,319	0
Restricted Stock Units
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments exercised or vested in share-based payment arrangement							309,237
Options granted (in shares)							273,390	1,052,236
Options exercised (in shares)							(309,237)
Restricted Stock Units | Year Of Issue, 2017, Expiry Date April 26, 2027
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments exercised or vested in share-based payment arrangement							309,237
Restricted Stock Units | Year Of Issue, 2018, Expiry Date March 9, 2028
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of other equity instruments exercised or vested in share-based payment arrangement							0
EMI
Disclosure of terms and conditions of share-based payment arrangement [line items]
Ending balance (in shares)							213,984
EMI | Year Of Issue, 2014, Expiry Date May 15, 2024
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 1.75
Beginning balance (in shares)							49,998
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							0
Ending balance (in shares)							49,998	49,998
EMI | Year Of Issue, 2015, Expiry Date January 29, 2025
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 1.25
Beginning balance (in shares)							41,997
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							0
Ending balance (in shares)							41,997	41,997
EMI | Year Of Issue, 2016, Expiry Date February 2, 2026
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise of options | £							£ 2
Beginning balance (in shares)							21,996
Options granted (in shares)							0
Options forfeited (in shares)							0
Options expired (in shares)							0
Ending balance (in shares)							21,996	21,996

Share-based payments charge -_2

Share-based payments charge - Disclosure of number and weighted average exercise prices of other equity instruments (Details) - Restricted Stock Units - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Beginning balance (in shares)	1,052,236	0
Options granted (in shares)	273,390
Options exercised (in shares)	(309,237)
Options forfeited (in shares)	(153,916)
Ending balance (in shares)	862,473	1,052,236
Year Of Issue, 2017, Expiry Date April 26, 2027
Disclosure of terms and conditions of share-based payment arrangement [line items]
Beginning balance (in shares)	1,052,236
Options granted (in shares)	0
Options exercised (in shares)	(309,237)
Options forfeited (in shares)	(13,012)
Ending balance (in shares)	729,987	1,052,236
Year Of Issue, 2018, Expiry Date March 8, 2028
Disclosure of terms and conditions of share-based payment arrangement [line items]
Beginning balance (in shares)	0
Options granted (in shares)	273,390
Options exercised (in shares)	0
Options forfeited (in shares)	(140,904)
Ending balance (in shares)	132,486	0

Share-based payments charge - O

Share-based payments charge - Outstanding and exercisable share options by scheme (Details)	Dec. 31, 2018GBP (£)shares	Dec. 31, 2017GBP (£)shares	Dec. 31, 2016GBP (£)shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding (in shares) | shares	8,752,114	7,527,458	3,037,296
Exercisable (in shares) | shares	3,542,884	797,333
Weighted average exercise price in £ for Outstanding (pounds per share) | £	£ 1.53	£ 1.53	£ 1.87
Weighted average exercise price in £ for Exercisable (pounds per share) | £	£ 1.66	£ 2.04
Unapproved Scheme
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding (in shares) | shares	8,538,130
Exercisable (in shares) | shares	3,336,232
Weighted average exercise price in £ for Outstanding (pounds per share) | £	£ 1.49
Weighted average exercise price in £ for Exercisable (pounds per share) | £	£ 1.57
EMI
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding (in shares) | shares	213,984
Exercisable (in shares) | shares	206,652
Weighted average exercise price in £ for Outstanding (pounds per share) | £	£ 3.06
Weighted average exercise price in £ for Exercisable (pounds per share) | £	£ 3.09
Unapproved And EMI Share Option Schemes
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding (in shares) | shares	8,752,114
Exercisable (in shares) | shares	3,542,884
Weighted average exercise price in £ for Outstanding (pounds per share) | £	£ 1.53
Weighted average exercise price in £ for Exercisable (pounds per share) | £	£ 1.66

Share-based payments charge -_3

Share-based payments charge - Number of options granted, expired and the weighted average exercise price of options (Details)	Sep. 20, 2018shares	Aug. 09, 2018shares	Sep. 13, 2017shares	May 26, 2017shares	May 18, 2017shares	May 02, 2017shares	Dec. 31, 2018GBP (£)shares	Dec. 31, 2017GBP (£)shares
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Beginning balance (in shares)							7,527,458	3,037,296
Options granted (in shares)				330,824	5,539,080	47,653,100	2,090,847
Options exercised (in shares)	(251,125)	(58,112)	(133,333)					(133,333)
Options forfeited (in shares)							(799,524)
Options expired (in shares)							(66,667)	(33,333)
Ending balance (in shares)							8,752,114	7,527,458
Exercisable (in shares)							3,542,884	797,333
Beginning balance, Weighted average exercise price in £ for Outstanding (pounds per share) | £							£ 1.53	£ 1.87
Exercised, Weighted average exercise price in £ for Outstanding (pounds per share) | £								1.10
Forfeited, Weighted average exercise price in £ for Outstanding (pounds per share) | £							1.43
Expired, Weighted average exercise price in £ for Outstanding (pounds per share) | £							1.75	1.90
Ending balance, Weighted average exercise price in £ for Outstanding (pounds per share) | £							1.53	1.53
Weighted average exercise price in £ for Exercisable (pounds per share) | £							£ 1.66	£ 2.04
Employees
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options granted (in shares)							1,222,089	3,150,846
Granted, Weighted average exercise price in £ for Outstanding (pounds per share) | £							£ 1.46	£ 1.32
Directors
Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]
Options granted (in shares)							868,758	1,505,982
Granted, Weighted average exercise price in £ for Outstanding (pounds per share) | £							£ 1.46	£ 1.32

Share-based payments charge - E

Share-based payments charge - Equity instruments other than options granted (Details) - Restricted Stock Units - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Beginning balance (in shares)	1,052,236	0
Options granted (in shares)	273,390
Ending balance (in shares)	862,473	1,052,236
Number of other equity instruments exercised or vested in share-based payment arrangement	(309,237)
Restricted stock units forfeited (in shares)	(153,916)
Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted (in shares)	136,404	705,841
Directors
Disclosure of terms and conditions of share-based payment arrangement [line items]
Options granted (in shares)	136,986	346,395

Trade and other payables (Detai

Trade and other payables (Details) - GBP (£) £ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Subclassifications of assets, liabilities and equities [abstract]
Trade payables	£ 2,839	£ 1,214
Other payables	12	74
Accruals	4,882	5,866
Total trade and other payables	£ 7,733	£ 7,154

Assumed contingent obligation_3

Assumed contingent obligation related to the business combination - Narrative (Details) - GBP (£) £ in Thousands	Sep. 19, 2006	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about business combination [line items]
Assumed contingent obligation		£ 996	£ 875	£ 802
Discount percent			12.00%
Rhinopharma Limited
Disclosure of detailed information about business combination [line items]
Increase in value of the assumed contingent obligation		£ 121	£ 73
Discount percent	12.00%	12.00%
Reported change to the value of the liability		£ 121	£ 100

Assumed contingent obligation_4

Assumed contingent obligation related to the business combination - Reconciliation of changes in contingent liabilities (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Reconciliation of changes in contingent liabilities recognised in business combination [abstract]
Beginning balance	£ 875	£ 802
Impact of changes in foreign exchange rates	15	(23)
Unwinding of discount factor	106	96
Ending balance	£ 996	£ 875

Assumed contingent obligation_5

Assumed contingent obligation related to the business combination - Reported change to the value of the liability (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about business combination [line items]
Assumed contingent obligation	£ 996	£ 875	£ 802
Rhinopharma Limited
Disclosure of detailed information about business combination [line items]
Change in value of the assumed contingent obligation	£ 121	£ 73
Revenue assumption, % lower	10.00%
Revenue assumption, % higher	10.00%
Risk assumption, % lower	1.00%
Risk assumption, % higher	1.00%
Discount Rate, 1% Variable
Disclosure of detailed information about business combination [line items]
Contingent liabilities recognised in business combination, variable up	£ 954
Assumed contingent obligation	996
Contingent liabilities recognised in business combination, variable down	1,040
Revenue Concentration Risk, 10% Variable
Disclosure of detailed information about business combination [line items]
Contingent liabilities recognised in business combination, variable up	1,026
Assumed contingent obligation	996
Contingent liabilities recognised in business combination, variable down	£ 966

Warrants - Narrative (Details)

Warrants - Narrative (Details) £ / shares in Units, £ in Thousands	Apr. 26, 2017GBP (£)	Feb. 10, 2017	Feb. 08, 2017	Jul. 29, 2016GBP (£)shareswarrant£ / shares	Dec. 31, 2018GBP (£)shareswarrant£ / shares	Dec. 31, 2017GBP (£)shares£ / shares	Dec. 31, 2016GBP (£)	Sep. 13, 2017£ / shares	Jul. 31, 2016shareswarrant
Disclosure of classes of share capital [line items]
Number of units issued (in shares) | shares				31,115,926	1,555,796,345
Placing price (in pounds per unit) | £ / shares				£ 1.4365	£ 0.02873
Number of ordinary shares (in shares) | shares				1					1
Number warrants (in warrants) | warrant				1					1
Number of shares subscribed (in shares) | shares				0.4
Exercise price percent				120.00%
Exercise price (pounds per share) | £ / shares								£ 1.10
Number of shares subscribed from warrant maximum (in shares) | shares					622,318,538
Change in fair value				£ 9,000
Warrant proceeds				35,700
Transaction costs allocated to the issue of warrants (note 19)	£ 408			£ 2,900		£ 7,453	£ 2,325
Warrants forfeited (in shares) | shares					799,524
Consolidation of shares		0.02	0.02		0.02
Exercise price (pence per share) | £ / shares					£ 0.034476
Fair value warrant					£ 2,492	£ 1,273	£ 7,923
Variance recorded					£ (1,200)
Warrants
Disclosure of classes of share capital [line items]
Exercise price (pounds per share) | £ / shares				£ 1.7238	£ 1.7238	£ 1.7238
Number of shares subscribed from warrant maximum (in shares) | shares				12,401,262	12,401,262	12,401,262
Transaction costs allocated to the issue of warrants (note 19)				£ 600
Warrants forfeited (in shares)					0	45,108
Ordinary shares
Disclosure of classes of share capital [line items]
Transaction costs allocated to the issue of warrants (note 19)				£ 2,300

Warrants - Assumptions in apply

Warrants - Assumptions in applying the Black-Scholes model, fair value warrants (Details) - £ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Sep. 13, 2017	Jul. 29, 2016
Disclosure of classes of share capital [line items]
Warrants (in shares)	622,318,538
Exercise price (pounds per share)			£ 1.10
Warrants
Disclosure of classes of share capital [line items]
Warrants (in shares)	12,401,262	12,401,262		12,401,262
Exercise price (pounds per share)	£ 1.7238	£ 1.7238		£ 1.7238
Risk-free interest rate	0.76%	0.42%
Expected term to exercise	3 years 4 months 24 days	1 year 9 months 15 days
Annualized volatility	60.72%	47.35%
Dividend rate	0.00%	0.00%

Warrants - Fair value adjustmen

Warrants - Fair value adjustments (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Reconciliation Of Changes in Warrants Outstanding [Roll Forward]
Beginning balance	£ 1,273	£ 7,923
Fair value adjustments recognized in loss	1,219	0	£ 0
Fair value adjustments recognized in profit	0	6,650	1,068
Ending balance	£ 2,492	£ 1,273	£ 7,923

Warrants - Effect when underlyi

Warrants - Effect when underlying parameters deviate (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of share capital, reserves and other equity interest [Abstract]
Variable up, Volatility (up / down 10% pts)	£ 3,262
Base case, Volatility (up / down 10% pts)	2,492	£ 1,273	£ 7,923
Variable down, Volatility (up / down 10% pts)	£ 1,738
Volatility (up/down), percentage	10.00%
Time to maturity (up, down), months	6 months

Financial commitments (Details)

Financial commitments (Details) - Land and Buildings - GBP (£) £ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Operating lease obligations:
Minimum lease payments payable under non-cancellable operating lease	£ 600	£ 568
Within one year
Operating lease obligations:
Minimum lease payments payable under non-cancellable operating lease	572	291
Between one and five years
Operating lease obligations:
Minimum lease payments payable under non-cancellable operating lease	£ 28	£ 277

Related parties transactions _2

Related parties transactions and other shareholder matters (Details) - GBP (£) £ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Chief executive officer
Disclosure of transactions between related parties [line items]
Number of ordinary shares purchased in related party transaction (in shares)	3,250
Amount of ordinary shares purchased in related party transaction	£ 5
Chairman
Disclosure of transactions between related parties [line items]
Number of ordinary shares purchased in related party transaction (in shares)	12,000
Amount of ordinary shares purchased in related party transaction	£ 14	£ 28
Non-executive director
Disclosure of transactions between related parties [line items]
Amount of ordinary shares purchased in related party transaction		£ 234
Key management personnel of entity or parent
Disclosure of transactions between related parties [line items]
Amounts receivable, related party transactions	126
Consultancy services provided	£ 26
Vivo Capital, OrbiMed And Abingworth | Entities with joint control or significant influence over entity
Disclosure of transactions between related parties [line items]
Percent of issued ordinary shares	6.50%